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Over two decades ago, the proteasome was considered a risky or even untenable therapeutic target. 
Today proteasome inhibitors (PIs) are a mainstay in the treatment of multiple myeloma (MM) and have 
sales in excess of three billion US dollars annually. More importantly, the availability of PIs has greatly 
improved the survival and quality of life for patients with MM. Carfilzomib (CFZ) is the second-in-
class PI with much improved efficacy and safety profiles over bortezomib, the first-in-class PI, for MM 
therapy. Despite the remarkable efficacy of CFZ against MM, the clinical trials in patients with solid 
cancers yielded rather disappointing results with minimal clinical benefits. The potential for 
improvement remains and the development and optimal use of PIs for solid cancer therapy continues to 
be an active area of research. Rapid degradation of CFZ in vivo and its poor penetration to tumor sites 
is considered to be major factors limiting its efficacy against solid cancers. To expand the utility of CFZ 
to solid cancer therapy, the aim was to overcome the pharmaceutical limitations of CFZ, and current 
findings may provide important insights in the development of next-generation PIs. As one of 
approaches to improve the pharmacokinetic profiles of CFZ, a novel polymer micelle-based formulation 
of CFZ was developed. In the previous report, polymer micelles (PMs) composed of biodegradable 
block copolymers poly(ethylene glycol)-poly(caprolactone) (PEG-PCL) were shown to improve the 
metabolic stability of CFZ in vitro. In Chapter I, in vivo anticancer efficacy and pharmacokinetic 
 II 
profiles were assessed using CFZ-loaded PM composed of PEG-PCL-deoxycholic acid (CFZ-PM). 
Despite in vitro metabolic protection of CFZ, CFZ-PM displayed in vivo anticancer efficacy in mice 
bearing human lung cancer xenograft (H460) comparable to that of the clinically used cyclodextrin-
based CFZ (CFZ-CD) formulation. The plasma pharmacokinetic profiles of CFZ-PM were also 
comparable to those of CFZ-CD. The residual tumors that persisted in xenograft mice receiving CFZ-
PM displayed an incomplete proteasome inhibition. In summary, these results showed that despite its 
favorable in vitro performances, CFZ-PM formulation did not improve in vivo anticancer efficacy and 
accessibility of active CFZ to solid cancer tissues over CFZ-CD. Thus, it seems to be necessary to 
consider potential confounding factors in translating in vitro results to in vivo settings and to develop 
another type of nanoformulation with an enhanced in vivo stability.  In Chapter II, it was investigated 
whether a nanocrystal (NC) formulation enhances in vivo stability and anticancer efficacy of CFZ 
against breast cancer. The surface of NC was coated with albumin in order to enhance the formulation 
stability and drug delivery to tumors via interactions with albumin-binding proteins located in and near 
cancer cells. The novel albumin-coated NC formulation of CFZ (CFZ-alb NC) displayed improved 
metabolic stability and enhanced cellular interactions, uptake, and cytotoxic effects in breast cancer 
cells in vitro. CFZ-alb NC also showed greater anticancer efficacy in a murine 4T1 orthotopic breast 
cancer model than CFZ-CD. Overall, these results demonstrated the potential of CFZ-alb NC as a viable 
formulation for breast cancer therapy. These studies may provide valuable insights into the future efforts 
to validate the potential of CFZ-based therapy for breast cancer and to develop effective CFZ delivery 
strategies that can be used to treat solid cancers. 
Keywords; proteasome inhibitor carfilzomib, nanoformulation, polymer micelle, nanocrystal, albumin, 
solid cancers 
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*This chapter (section 1 to 4.3.) includes the introductory sections that were published as 
a review article ‘Next-generation proteasome inhibitors for cancer research’ in 
Translational Research (Volume 198, pages 1-16, August 2018) and the newly added 
section 4.4. that is focused on novel formulations and delivery systems for proteasome 





The proteasome is a large multi-protease complex and is responsible for the controlled degradation of 
more than 80% of cellular proteins [1]. As such, the proteasome plays a key role in maintaining cellular 
protein homeostasis and regulates numerous biological processes, such as cell survival, DNA repair, 
apoptosis, signal transduction, and antigen presentation. Structurally, the 20S mammalian proteasome 
consists of a cylinder made of four stacked rings: two identical outer α-rings and two identical inner β-
rings, each containing seven distinct but related subunits (Figure 1). In mammalian proteasomes, each 
β-ring harbors three catalytic β-subunits (β1, β2 and β5) which display different substrate preferences, 
referred to as caspase-like (C-L), trypsin-like (T-L) and chymotrypsin-like (CT-L) activities, 
respectively [2]. The active sites of these catalytic subunits face inward, accepting peptide substrates 
from the proteasome’s hollow inner chamber. By controlling which proteins enter its inner chamber, 
the proteasome is able to degrade proteins in a highly-regulated fashion [3]. Proteins targeted for 
proteasome-mediated degradation are typically tagged by the covalent attachment of polyubiquitin 
chains (“ubiquitination”) before being recognized and degraded by the proteasome complex. The 
concerted action of ubiquitination by a series of enzymes and proteolysis by the proteasome complex 
is collectively known as the ubiquitin-proteasome system (UPS).  Over the past three decades, the UPS 
has been extensively explored as a target for drug discovery [4, 5], culminating in the remarkable 
clinical success of proteasome inhibitor (PI) drugs in the treatment of hematological malignancies 
including multiple myeloma (MM).  Although a great amount of effort has been made to develop agents 
which target other UPS components such as ubiquitin ligases and deubiquitinases, to date only the 
proteasome has been successfully exploited as a therapeutic target to treat human disease.  
Following the clinical success of proteasome-targeted therapies for cancer treatment, much 
effort has been made to address the limitations associated with existing PI drugs. Like almost all cancer 
therapeutics, cancer resistance, either acquired or de novo, is a major hurdle for PI drugs. So far, various 
resistance mechanisms have been reported for PI drugs in preclinical and clinical settings [6, 7] but  
remain unsettled. In recent years, there have been increasing attempts to design novel PIs that can 
overcome resistance or bypass cross-resistance to existing PI drugs [8]. In addition, PI drugs have 
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Figure 1. The structure and function of 26S proteasome in the ubiquitin-proteasome system (UPS).  
Proteins targeted for proteasome-mediated degradation are typically tagged by the covalent attachment 
of polyubiquitin chains of at least 4 ubiquitin (Ub) moieties (“ubiquitination”). This ubiquitination is 
carried out by the concerted action of three distinct enzymes, E1 (Ub activation), E2 (Ub conjugation), 
and E3 (Ub ligation). Subsequently, ubiquitinated proteins are recognized, unfolded and de-
ubiquitinated by the lid of 26S proteasome (19S regulatory particles composed of ATPase and non-
ATPase subunits). The proteolysis takes place at the inner chamber inside the 20S core, generating short 
peptide fragments of typically 2 to 24 amino acid residues. The 20S core consists of two outer α rings 
and two inner β rings, each containing seven distinct subunits. Each β ring harbors three catalytic β-
subunits (β1, β2 and β5) which display different substrate preferences and their activities are commonly 
referred to as caspase-like (C-L), trypsin-like (T-L) and chymotrypsin-like (CT-L) activities, 
respectively. Among the three catalytic β-subunits, β5 subunit is the major target of current proteasome 
inhibitor drugs via their interactions with the catalytic threonine (Thr) residue. 
 
shown exquisite efficacy in treating MM and other hematological malignancies, but not solid cancers 
[9]. The lack of therapeutic efficacy of PI drugs against solid cancers has often been attributed in part 
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to their poor pharmacokinetic (PK) profiles including their short circulation time and insufficient 
distribution to proteasome targets located in solid tumor tissues [10]. Moreover, our understanding 
remains limited on how the kinetics (both the magnitude and duration) and mode of proteasome 
inhibition can impact the pharmacodynamic (PD, such as efficacy and safety) profiles of PI drugs. 
Moving forward, an enhanced the understanding of the PKs and PDs of PI drugs and of the relationship 
between them is needed. Here, we provide a brief overview of three clinically used PI drugs for cancer 
therapy focusing on PK/PD considerations and also summarize current efforts to develop next-
generation PI drugs and to improve the current PI therapy via novel drug delivery systems. 
 
2. Proteasome inhibitor drugs in clinical use for cancer therapy 
Currently, three PIs are in clinical use, bortezomib (BTZ, VelcadeÒ, the first-in-class PI drug with US 
FDA approval in 2003), carfilzomib (CFZ, KyprolisÒ, the second-in-class PI drug with US FDA 
approval in 2012) and ixazomib (IXZ, NinlaroÒ, the first oral PI drug with US FDA approval in 2015) 
(Figure 2). Although these PI drugs have brought tremendous improvements to the treatment of MM, 
earlier efforts to develop therapeutics targeting the proteasome had received considerable skepticism. 
This skepticism was not unreasonable, given the fundamental roles and abundant presence of the 
proteasome in all types of cells. Despite such skepticism, early preclinical results in models of human 
cancer were very promising, especially for MM and other hematological malignancies [11, 12]. 
Propelled by exemplary academic-industrial partnerships, BTZ was successfully developed as the first-
in-class PI drug with record efficiency in drug development and became a blockbuster drug in cancer 
therapy [13]. The clinical success of BTZ has prompted the development of CFZ and IXZ soon after. 
Below is a brief account of discovery and development efforts of these clinically used PI drugs.   
 
Figure 2. Structures of proteasome inhibitors in clinical use. 
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2.1. Bortezomib (BTZ, PS-341, VelcadeÒ): Rise of proteasome inhibitors as an anticancer agent 
The earliest efforts to identify specific PIs began in the late 1980’s [14, 15]. These early inhibitors were 
used to probe the function of the proteasome itself and to examine its biological role within the cell. 
The path towards PIs as therapeutic agents began with research into the role of the UPS in muscle 
wasting. Goldberg et al. proposed that upregulation of the UPS could explain the muscle wasting 
phenomenon observed in conditions such as sepsis, cancer, and burn injuries [16]. They further 
suggested that muscle wasting could be treated with PIs by suppressing excessive proteolysis of muscle 
proteins. In subsequent efforts, a highly potent PI, PS-341, now known as BTZ, was identified [17]. 
Pre-clinical studies soon revealed that BTZ is highly effective against various types of cancers [12, 18].  
Structurally, BTZ is a dipeptide boronic acid that forms a coordinate covalent bond with the 
catalytic threonine residue of the proteasome’s β5 and β1 subunits [19]. As a result, BTZ displays a 
potent inhibitory effect on the CT-L activity and to a lesser extent on the C-L activity of the 20S 
proteasome [20] (Table 1). In addition to its high affinity binding to the proteasome, BTZ also 
demonstrated nanomolar cytotoxic potencies against a variety of cancer cell lines, in particular, those 
derived from MM [12, 21]. These in vitro findings also translated into promising in vivo efficacies in 
mouse xenograft models of both hematological and non-hematological malignancies [12, 18, 22].  
Prompted by strong preclinical data, several early phase clinical trials had investigated BTZ 
for its safety and tolerability in over 200 cancer patients by late 2001 [23]. BTZ was relatively well 
tolerated with adverse events consisting of low-grade fever, fatigue, thrombocytopenia, and in some 
patients, peripheral neuropathy. BTZ soon received US FDA fast-track approval for the treatment of 
relapsed and refractory MM in 2003, based on the outstanding efficacy results from the phase II open-
label SUMMIT trial [24]. BTZ’s clinical efficacy was further proven in combination with other 
therapeutic agents, leading to a full US FDA approval in 2005 as a second-line MM therapy [25] and 
in 2008 as a first-line therapy for patients with newly diagnosed MM [26]. BTZ also received approval 
for use in patients with previously-treated mantle cell lymphoma from the US FDA in 2014 and from 
the European Medicines Agency in 2012 [27]. Today BTZ is commonly used as a first-line agent in 
combination with other anti-myeloma agents, for example, immunomodulatory agents such as 
 6 
Table 1. Proteasome inhibitors in clinical use: Their interactions with the proteasome target 
Drug name Pharmacophore Binding mode IC50 (nM) 
CT-L C-L T-L 
Bortezomib boronic acid reversible 2 ~ 31 14.5 ~ 401 12001 
7.92 532 5902 
Carfilzomib epoxyketone irreversible 5.1 ~ 5.73 2,4004 3,6004 
Ixazomib boronic acid reversible 55 405 > 10,0005 
2.8 ~ 4.11 311 35001 
1 Calu-6 cells were treated with PIs for 1 hr. Proteasome-Glo assay [28]  
2 Purified human erythrocyte 20S proteasomes [29]  
3 Purified human 20S proteasomes [30]  
4 Purified human 20S proteasomes [31]  
5 MM.1S cells were treated with ixazomib for 3 h and harvested. Cell extracts were then analyzed for CT-L 
(Chymotrypsin-like), C-L (Caspase-like), and T-L (Trypsin-like) activity assay [32] 
 
thalidomide or lenalidomide, cytotoxic drugs like melphalan, and glucocorticoids such as 
dexamethasone or prednisone. BTZ has also served as a proof-of-concept paving the way for two 
additional US FDA-approved PI drugs. While a number of clinical trials have investigated the 
possibility of extending the therapeutic effects of BTZ beyond MM, the results so far have been 
disappointing [10, 33].   
BTZ is currently formulated for intravenous or subcutaneous injections (as a lyophilized 
powder with mannitol). An earlier study explored the possibility of oral administration [18], but this 
approach was not further pursued due to low bioavailability (~11% in mice [34]). BTZ was shown to 
have rapid and wide biodistribution profiles in preclinical studies [12]. Interestingly, a recent 
publication reported that the biodistribution of BTZ in various tissues is impacted by the tissue density 
of the proteasome which BTZ tightly and reversibly binds to [35]. This study further demonstrated that 
saturation of proteasome binding sites at high doses of BTZ can contribute to non-dose-proportional 
PK behaviors of BTZ.  Similar to these preclinical findings, the results from a phase I clinical trial also 
indicated that BTZ displays a large volume of distribution (> 400 L) in patients with solid cancers [36]. 
Subsequent clinical trials reported similar findings on the PK profiles of BTZ (detailed reviews 
available [37], Table 2). When the metabolism of BTZ was investigated using human liver microsomes, 
BTZ was converted to pharmacologically inactive metabolites primarily via oxidative deboronation, 
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mediated by multiple cytochrome P450 enzymes (CYPs) with their relative contribution in the 
following order, CYP3A4, CYP2C19, CYP2D6, CYP1A2 and CYP2C9 [38, 39]. Consistent with these 
results, the systemic exposure of BTZ was increased and decreased with co-administration of 
ketoconazole (a CYP3A4 inhibitor) and rifampicin (a potent CYP3A4 inducer), respectively [40, 41]. 
On the other hand, co-administration of omeprazole (a CYP2C19 inhibitor) had only a minimal impact 
on the PK profiles of BTZ in patients with advanced solid cancers [42]. Given the importance of hepatic 
metabolism in the elimination of BTZ, patients with hepatic dysfunction may require dose adjustment, 
but no guideline or recommendation is available yet. In preclinical studies, the majority of the radio-
labeled BTZ was excreted into bile duct (~66%) with the remainder excreted into the urine [12]. In a 
clinical study, patients with renal impairment responded to BTZ therapy similar to those with normal 
renal function [43].  
Being the first-in-class PI drug, BTZ also became the first to be explored for the relationship 
between proteasomal inhibition (both the magnitude and duration) and anticancer efficacy in vivo. 
When the PK/PD profiles were compared in mouse xenograft models which responded differently to 
BTZ, the results indicated that both drug penetration and proteasome inhibition were much attenuated 
in mice carrying poorly perfused xenograft tumors which did not respond to BTZ treatment [44]. These 
findings were applied to the development of next-generation PI drugs as well as novel drug delivery 
systems. For example, in order to modulate the magnitude and duration of proteasome inhibition by 
BTZ, several groups investigated the potential utility of nanoformulations including the design of 
prodrugs or bone-targeting moieties [45-47]. However, the results from these efforts have yet to be 
translated into clinical application. 
Despite the remarkable clinical success achieved by BTZ, several limitations have emerged. 
Like many other cancer therapies, a subset of patients responds to BTZ therapy while others do not. 
Even those who initially respond to BTZ therapy almost inevitably develop resistance over time [48]. 
The median duration of clinical response was typically about 12 months [49, 50]. The mechanisms 
underlying cancer resistance to BTZ have been actively investigated, yielding various potential 
strategies to overcome resistance including the development of PI drugs based on novel structural 
scaffolds [51]. In addition to drug resistance, BTZ therapy is associated with the severe adverse effect 
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of peripheral neuropathy, which was later attributed to its off-target interactions with a serine protease 
(HtrA2/Omi) involved in neuronal survival [52, 53]. This dose-limiting toxicity of BTZ was 
substantially alleviated by administering the drug via subcutaneous injection [54] or by implementing 
once-weekly dosing [55, 56]. These issues prompted the development of next-generation PIs with more 
favorable safety profiles and fewer off-target interactions.  
2.2. Carfilzomib (CFZ, PR-171, Kyprolis®): Novel mode of proteasome inhibition   
The second-in-class PI drug CFZ (Kyprolis®, developed by Proteolix/Onyx Pharmaceuticals and now 
available through Amgen) received its fast-track US FDA approval in 2012, based on its efficacy and 
safety results in patients with relapsed and refractory MM [57]. The development of CFZ was initiated 
by the identification of the proteasome as the major target of the natural product epoxomicin [58]. The 
design and synthesis of a biotinylated chemical probe led to the discovery that the epoxyketone group 
of epoxomicin covalently binds to the proteasome with an exceptional selectivity over other types of 
proteases. Subsequent efforts were made to build a library of epoxomicin analogs and identified a lead 
candidate, YU-101, based on their potent anticancer activities [59, 60]. Later, YU-101 was further 
modified to yield CFZ which displayed very promising preclinical results [31].  
Structurally, CFZ is a tetrapeptide harboring an epoxyketone as its pharmacophore and it forms 
an irreversible, covalent bond with proteasome catalytic subunits, predominantly β5 (Table 1). The 
exquisite selectivity of CFZ toward the proteasome is achieved by the formation of two covalent bonds, 
one with the catalytic Thr1Oγ nucleophile and a second with the adjacent Thr1N amino group. Based 
on high-resolution co-crystal structures between the proteasome and various epoxyketone-based 
inhibitors, the formation of a 1, 4-oxazepano adduct has been identified between the epoxyketone of 
these inhibitors and the catalytic threonine residue within the β5 active site [61, 62]. Due to this 
proteasome-selective mechanism of action, CFZ has afforded much improved safety profiles. 
Additionally, the irreversible nature of the interaction between CFZ and the proteasome allows it to 
achieve sustained and durable proteasome inhibition, which may contribute to its efficacy even in the 
presence of resistance to BTZ [63]. Of note, the irreversible modification of the proteasome target by 
CFZ or other peptide epoxyketones have also been exploited to develop activity-based probes (ABPs) 
that allow for covalent labeling of functional proteasomes or profiling of proteasome activity under 
 
 
Table 2. Clinically used dosing regimens and pharmacokinetic (PK) parameters reported for FDA-approved proteasome inhibitor drugs. 
Drug name Current clinical dosing regimens 
Tested dosing regimens and reported PK parameters 
Ref. 




1.3 mg/m2 IV on 
days 1, 4, 8 & 11 of 
21-day cycles 
1.45 mg/m2, IV (C1D1) CL, 75.3 (51.2) L/h; Vss, 416 (158) L; t1/2, 8.68 (4.16) 
h 
Phase I trials in patients with 
advanced solid cancers; dose-
proportionality in PK parameters not 
established 
[36] 
1.6 – 2.0 mg/m2, IV (C1D1) CL, 63.7-112 (29.8-126) L/h; Vss, 696-979 (357-473) 
L; t1/2, 10.4-14.8 (4.96-10.4) h 
1.3 mg/m2, IV. 
single dose (C1D1) vs. 
multiple doses (C1D11, C1D3, 
& C3D11) 
single dose: CL, 111.6 (73.6) L/h; Vss, 1540 (2730) L; 
t1/2, 11.5 (12.7) h 
multiple doses: CL, 18.2-28.0 (9.2-19.8) L/h; Vss, 
1613-2213 (1125-2730) L; t1/2, 75.6-108.6 (34.6-64.8) 
h 
Upon repeated dosing, CL decreased 
while the systemic exposure and t1/2 
increased. 
[64] 
1.0 mg/m2 IV (C1D11) vs.  
2.5 mg/m2 SC (C1D11) 
SC: Cmax, 20.4 (8.87) ng/mL; Tmax, 30 (5-60) min; 
AUClast, 155 (56.8) ng·h/mL 
IV: Cmax, 223 (101) ng/mL; Tmax, 2 (2-5) min; AUClast, 
151 (42.9) ng9·h/mL 
Phase III study in patients with 
RRMM. Equivalent systemic 






20 mg/m2 on days 1 
& 2; if tolerated, 
escalated to 27 
mg/m2 (IV infusion, 
2-10 min) or 56 
mg/m2 (IV infusion, 
30 min) on day 8 of 
cycle 1; followed by 
tolerated dose on 
days 9, 15 & 16 of a 





20 mg/m2, IV (C1D1) CL, 659 (353) L/h; Vss, 108 (71) L; t1/2, 0.66 (0.48) h Phase I trial in patients with RRMM. [66] 
20 mg/m2, 2-10 min IV 
infusion on D1, 2, 8, 9, 15 & 
16 
D1: CL, 146 (22) L/h  
D16: CL, 136 (53) L/h 
CL exceeded hepatic blood flow. [67] 
2-10 min IV infusion. 
20 mg/m2 on D1 & 2 à 27 and 
36 mg/m2 on D8, 9, 15 & 16 
20 mg/m2 (D1): CL, 263 (398) L/h; Vss, 27.7 (48.6) L; 
t1/2, 0.44 (0.15-2.20) h 
20 mg/m2 (D16): CL, 136 (52.8) L/h; Vss, 7.75 (3.77) 
L; t1/2, 1.10 (1.00-1.13) h 
27 mg/m2 (D16): CL, 150 (30.9) L/h; Vss, 11.1 (4.45) 
L; t1/2, 0.35 (0.26-0.92) h 
Phase I/II trials in patients with 
advanced solid cancers. 
Rapid systemic CL, large Vss and 
very short elimination half-lives. 
[68] 
30 min IV infusion.  
20 mg/m2 on D1 & 2 à 36, 45, 
56 or 70 mg/m2 on D8, 9, 15 & 
16  
20 mg/m2 (C1D1): CL, 143 (56.6†) L/h; t1/2, 0.837 h 
27 mg/m2 (C2D16): CL, 102 L/h; t1/2, 0.973 h 
56 mg/m2 (C2D16): CL, 118 (27.7†) L/h; t1/2, 0.875 h 
Phase I trial in patients with RRMM. 
Comparable PK properties between 
30 min and 2-10 min infusion. 
[69] 
30-min IV infusion.  
20 mg/m2 on D1 à  
45, 56, 70 or 88 mg/m2 on D8 
& 15 
 
20 mg/m2 (D1): CL, 146 (30.4†) L/h; t1/2, 0.64 (0.193-
1.29) h; AUClast, 260 (27.6†) ng·h/mL 
70 mg/m2 (D15): CL, 131 (28.6†) L/h; t1/2, 0.95 
(0.572-1.29) h; AUClast, 1030 (20.5†) ng·h/mL 
88 mg/m2 (D15): CL, 138 (34.3†) L/h; t1/2, 0.848 
(0.648-0.952) h; AUClast, 1190 (29.1†) ng·h/mL 
Phase I/II trials in patients with 
RRMM. Dose-proportional increase 






4 mg orally 
administered on days 
1, 8, & 15 of 28-day 
cycles 
0.24-3.95 mg/m2 on D1, 8 & 
15  
D1: Tmax, 1 (0.5-8.0) h 
D15: t1/2, 3.6- 11.3 days 
Rapid absorption and long terminal 
half-lives. 
2.23 mg/m2 is equivalent to 4.0 mg 
[71] 
0.24-2.23 mg/m2 on D1, 4, 8 & 
11 of 21-d cycles 
2 mg/m2 (D1): Tmax, 0.65 (0.25-3.97) h  
2 mg/m2 (D11): Tmax, 1 (0.5-23.6) h; t1/2, 3.3- 7.4 days 
[72] 
4 mg on D1, 8 & 15 CL, 2.0 (4.9‡) L/h; BA, 60%; Tmax, 1.5 (0.3-8) h Results from population PK 
modelling. 
[73] 
4 mg on D1, 8 & 15 Model parameter: CL, 1.86 L/h; BA, 58%;  Combination treatment with 
lenalidomide & dexamethasone in 
RRMM 
[74] 
Abbreviations: IV, intravenous; SC, subcutaneous; CL, clearance; Vss, volume of distribution at steady-state; t1/2, terminal half-life; Cmax, maximum plasma concentration; Tmax, 
time to Cmax; AUClast, area under the concentration–time curve from time 0 to the last time point; BA, bioavailability; RRMM, refractory or relapsed multiple myeloma; D, 
Day(s); C, cycle(s)  













diseased conditions or in response to cellular stimuli [75]. Such ABPs may be potentially used as 
diagnostics to detect disease or monitor response to therapy [76-78]. 
In 2005, phase I clinical trials with CFZ began and successfully identified the phase II 
recommended doses and dosing schedules that were further investigated in subsequent clinical trials 
[66, 79]. From early on, it was observed that a subset of patients who did not respond to BTZ-based 
therapy could still benefit from CFZ. Recently completed phase III clinical trials provided further 
evidence that CFZ-containing regimens can be effective against relapsed MM, including those patients 
who relapsed after receiving prior therapies including BTZ [80, 81]. In particular, the phase III 
ENDEAVOR trial was a head-to-head comparison of CFZ and BTZ in patients with relapsed or 
refractory MM [81]. In this trial, CFZ was shown to be superior to BTZ in extending overall survival 
of patients in the relapsed setting. In addition to its superior efficacy, the CFZ-containing regimen 
showed much improved safety profiles, especially in terms of peripheral neurotoxicity. While 
cardiovascular events were observed in CFZ-treated patients, no evidence was found of cumulative 
cardiac injury or ventricular dysfunction in the CFZ group. With these outstanding outcomes, CFZ is 
now part of a standard of care for relapsed or refractory MM and will likely evolve as part of frontline 
therapy in the near future.  
When the PK profiles of CFZ were initially assessed in rats, the results indicated very rapid 
clearance, short circulation time (plasma half-lives less than 1 h) and wide biodistribution [31, 82]. At 
all dose levels tested, the clearance of CFZ exceeded rat hepatic flow. In line with these in vivo results, 
CFZ was found to be rapidly metabolized in rat hepatocytes, but also in rat blood and in homogenates 
prepared from other tissues [82]. The major metabolites of CFZ were peptide fragments and the diol of 
CFZ, formed via peptidases and epoxide hydrolases, respectively. Similar to these preclinical results, 
early phase clinical trials also indicated that CFZ displays very short half-lives (12 ~ 40 min), rapid 
systemic clearance (116 ~ 263 L/h) and large volumes of distribution at steady state (9 ~ 28 L) at all 
dose levels tested (11, 15, 20, and 27 mg/m2) [66, 68] (Table 2). Plasma clearance of CFZ in humans 
also exceeded hepatic blood flow, further indicating a considerable contribution of extrahepatic 
mechanism to the overall elimination of CFZ [67]. Consistent with in vitro results showing only minor 
roles of CYP-mediated metabolism or renal excretion in the overall disposition of CFZ, the PK profiles 
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of CFZ were not impacted by co-administration with CYP inhibitors or inducers [67] or by renal 
impairment [83, 84]. 
Along with its structural and mechanistic differences from BTZ, CFZ offers a treatment option 
with greatly reduced risk of peripheral neuropathy. CFZ treatment is associated with different types of 
adverse effects including cardiovascular complications, hypertension, and heart failure, but overall 
these adverse effects are reversible and manageable with careful monitoring [85]. CFZ shares several 
adverse events with BTZ such as anemia, fatigue, and diarrhea. One potential downside of CFZ is its 
poor aqueous solubility. Despite the incorporation of a N-terminal morpholine ring to improve solubility, 
CFZ remains practically insoluble and the current formulation requires the use of a 50-fold excess of a 
b-cyclodextrin derivative to prepare an injectable solution. As with BTZ, CFZ is not suitable for oral 
administration and is susceptible to drug resistance in clinical use. These problems have prompted the 
development of additional next-generation PIs.  
2.3. Ixazomib (IXZ, MLN9708, Ninlaro®): First oral proteasome inhibitor drug 
With both BTZ and CFZ being administered only via intravenous or subcutaneous injection, there has 
been an unmet need for orally available PI drugs. In 2015, IXZ (Ninlaro®, Takeda Pharmaceuticals 
Limited) received its US FDA approval as the first orally bioavailable PI drug. Based on the promising 
efficacy observed in preclinical studies, IXZ rapidly advanced to clinical trials [28, 32]. IXZ, orally 
administered once a week (4 mg on days 1, 8, and 15 of 28-day cycles) in combination with 
lenalidomide plus dexamethasome, has now been approved in 40 countries including USA and the EU 
for the treatment of MM patients who have received one prior therapy, based on the superior results in 
clinical trials [72, 86]. IXZ also displayed a good safety profile with no significant inhibitory effect on 
HtrA2/Omi, a non-proteasomal target of BTZ previously linked to peripheral neuropathy [32, 86, 87]. 
IXZ is currently being investigated in several clinical trials as a single agent and in combination with 
other agents against multiple types of cancer (https://clinicaltrials.gov). 
Structurally, IXZ is a capped dipeptide boronic acid and preferentially and reversibly inhibits 
the CT-L activity of the proteasome as well as the C-L and T-L activities at high concentrations with 
potencies similar to BTZ [32]. However, the dissociation half-life of IXZ was significantly shorter than 
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that of BTZ (18 vs. 110 min), which may account for the faster recovery of proteasome activity (IXZ 
vs. BTZ, 69 vs. 20%) in cell-based assays and its larger volume of distribution in mice (IXZ vs. BTZ, 
20.2 vs. 4.3 L/kg) [28]. Although not examined, some of these differences may have contributed to the 
improved safety profiles of IXZ over BTZ, despite sharing the boronic acid residue as their 
pharmacophore.  
For oral administration, IXZ is formulated as a citrate ester prodrug (MLN9708) which is 
rapidly hydrolyzed to the pharmacologically active form (MLN2238) under physiological conditions 
[28]. In phase I clinical trials, orally administered IXZ was rapidly absorbed (mean Tmax, 0.5 ~ 1 h) and 
had a long terminal half-life (mean T1/2, 3.3 ~ 7.4 days in twice-weekly dosing; 3.3 ~ 11.3 days in 
weekly dosing) [71, 72] (Table 2). When tested using recombinant CYP enzymes in vitro, IXZ was 
metabolized by multiple CYPs at concentrations exceeding those observed clinically and deemed 
unlikely to incur potential drug-drug interactions [88]. Yet, co-administration with rifampin, a strong 
CYP3A inducer, led to substantial changes in the PK profiles of IXZ (Cmax and AUC decreased by 54% 
and 74%, respectively) [88]. Overall, the PK profiles of IXZ showed dose-proportional behaviors. 
Using the compiled clinical data from 755 patients treated with IXZ, Gupta et al. conducted population 
PK analyses and reported the following average estimates for PK parameters: absolute bioavailability 
(58%), volume of distribution (543 L), terminal phase half-life (9.5 days), and systemic clearance (1.86 
L/h) [74]. Systemic exposure to IXZ was affected by moderate or severe hepatic impairment [89], but 
not by renal impairment [74]. While IXZ has the potential to greatly improve the quality of life for 
patients with MM, its therapeutic advantages over BTZ or CFZ have yet to be investigated in 
randomized clinical trials.  
 
3. Drug resistance (acquired or de novo): Major hurdles in improving PI therapy 
Common in many cancer therapies, the issues of drug resistance also pose major hurdles for PI 
therapies. MM patients who initially respond to PI therapy almost inevitably develop resistance over 
time (acquired resistance). Once patients relapse with MM refractory to PI-based therapy, there are 
currently few effective treatment options left. While a subset of MM patients responds well to PI 
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therapy, others do not (de novo resistance). Several potential mechanisms for resistance to PI therapy 
have been proposed using cell-based model systems. Yet, those mechanisms await further validation 
in patients with MM and also in patients with solid cancers. For the lack of clinical benefits of PI 
therapy for solid cancers, it has been postulated that active PI drugs may have insufficient access to 
the proteasome target located in solid cancer cells (related to the PK issues). This possibility was 
supported in part by the preclinical results showing effective tumor growth suppression following 
direct intratumoral injection of PI drugs [12, 90]. In addition, intravenous dosing of BTZ was effective 
in mice harboring highly perfused xenograft tumors, but not poorly perfused ones [44]. Alternatively, 
it was also proposed that solid cancer cells may be inherently less sensitive to PI therapy than MM 
cells known for their elevated levels of proteotoxic stress or ER stress [91, 92].  To tease out why 
patients with solid cancers do not benefit from PI therapy, it would be necessary to develop PI drugs 
that can afford sufficient access to the proteasomes in solid cancer cells and/or to develop targeted 
drug delivery systems.     
Current understanding of resistance mechanisms for PI drugs, although not complete, has 
provided important platforms to screen for PI drugs that can potentially overcome resistance to existing 
PI drugs. Several reports observed the presence of mutations in the PSMB5 gene encoding the β5 
catalytic subunit from cancer cell line models resistant to BTZ and low levels of Xbp1, a key regulator 
of one arm of the unfolded protein response (UPR), in primary cells isolated from MM patients 
following BTZ therapy [93-96]. For cancer cell line models resistant to CFZ and epoxomicin, the 
upregulation of P-glycoprotein was reported to be causally linked to drug resistance [97, 98]. This 
information provided important guidance during the development of another epoxyketone-based PI, 
OPZ [30, 93]. The screening and optimization processes for OPZ and related compounds included the 
testing in cell lines expressing P-glycoprotein.  
 
4. Development strategies for next-generation proteasome inhibitors  
As discussed above, the discovery of next-generation PIs with improved PK/PD profiles could improve 
clinical outcomes for MM patients (especially those with resistance to existing PI therapy) and extend 
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therapeutic benefits to patients with solid cancers where existing PI drugs have proved largely 
ineffective. To achieve this goal, the following development strategies have been actively explored. 
Given that comprehensive reviews are already available on the first two strategies, we focused on the 
recent efforts to develop non-peptide-based PIs and drug delivery system. 
4.1. Immunoproteasome-selective inhibitors 
The immunoproteasome (iP) is a variant of the constitutive proteasome in which the constitutive 
catalytic subunits β1, β2 and β5 are replaced by their respective inducible counterparts β1i, β2i and β5i, 
under inflammatory conditions and certain pathological states including cancer. By targeting the iP, it 
may achieve more selective inhibition of the proteasomal activity in cancer cells, thereby widening the 
therapeutic window. Although iP inhibitors have been studied in the preclinical setting, to date none 
have entered clinical trials [99]. As the iP is strongly implicated in inflammatory pathways, iP-selective 
inhibitors are currently being investigated as potential anti-inflammatory agents. Detailed reviews on 
iP inhibitors are already available [100-102]. 
4.2. Peptide-based proteasome inhibitors  
The vast majority of existing PIs utilize a peptide backbone and an active warhead that interacts with 
the catalytic Thr residues of β-subunits with different mechanisms of action (e.g., aldehydes, vinyl 
sulfones or esters, boronates, epoxyketones, b-lactones). With the successful clinical development of 
the peptide boronates (BTZ and IXZ) and epoxyketone (CFZ), intense efforts have been underway to 
further refine the structure-activity relationship (SAR) and to identify compounds with optimal 
pharmacological profiles among peptide-based proteasome inhibitors. For further information on 
peptide-based PIs, comprehensive reviews are already available [103, 104].  
4.3. Non-peptide-based proteasome inhibitors 
From one of the earliest efforts to identify structurally-novel PIs via high-throughput screening, PI-083 
was identified as a non-peptide PI [105]. Utilizing a 2-chloro-1,4-naphthoquinone scaffold, PI-083 
preferentially inhibited the CT-L activity of the 20S proteasome (IC50: 1.0 µM) and inhibited T-L and 
C-L activities at slightly higher concentrations (IC50: 4.5 µM for both). When tested against a panel of 
10 solid cancer cell lines, PI-083 exerted cytotoxic effects with IC50 values ranging from 1.7 to 11 µM. 
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PI-083 was also effective in suppressing in vivo tumor growth in mouse xenograft models at a dose of 
1 mg/kg twice weekly. Based on docking results and the compound’s SAR, it is postulated that PI-083 
may act as a covalent PI with the chlorinated 2-carbon undergoing nucleophilic attack by the 
proteasome’s catalytic threonine residue [106]. Recovery of proteasome activity following incubation 
with PI-083 was slow, with only partial recovery of activity after 18 h. Attempts to improve PI-083’s 
inhibitory potency were generally unsuccessful and the SAR was highly sensitive to modification.  
A subsequent report from the same group identified PI-1840, a structurally-unrelated non-
peptide compound which potently and selectively inhibited the CT-L activity of the 20S constitutive 
proteasome (IC50: 27 nM) [107]. PI-1840 showed no appreciable inhibition of 20S proteasome T-L or 
C-L activity and had an IC50 value of greater than 1 µM against the CT-L activity of the iP. Analysis 
via mass spectrometry and dialysis confirmed that PI-1840 acts as a fully-reversible inhibitor. A panel 
of solid cancer cell lines displayed varying degrees of sensitivity to PI-1840 (IC50: 2.2 ~ 45.2 µM), and 
the cytotoxic potency appeared to correlate with the degree of proteasome inhibition achieved by PI-
1840. When tested in mice bearing MDA-MB-231 human breast cancer xenografts, PI-1840 (150 
mg/kg daily via intraperitoneal injection) effectively suppressed tumor growth, in contrast to no 
appreciable suppression in the control groups that received either BTZ (1 mg/kg twice weekly via 
intraperitoneal injection) or the vehicle only. No observable toxicity was noted in animals receiving 
high doses of PI-1840. The safety profiles observed with PI-1840 may be related to its high degree of 
selectivity for the constitutive β5 subunit relative to the iP subunit β5i and its lack of inhibition of T-L 
or C-L activities. Given that the existing PI drugs tend to target both β5 and β5i subunits with relatively 
low selectivity, it awaits further investigations to determine whether the selective inhibition of β5 by 
PI-1840 may be advantageous or disadvantageous in terms of anticancer efficacy.  The PK profiles of 
PI-1840 have not yet been published.   
Another non-peptide PI dubbed G4-1, based on a tri-substituted pyrazole scaffold, was reported 
by our own research group [108]. Identified via the combination of structure-based virtual screening 
and in vitro kinetic assays, G4-1 inhibits both β5 and β5i catalytic activities with IC50 values of 1.6 and 
2.4 µM, respectively. β1 and β1i subunits (C-L activity) were also inhibited at low micromolar 
concentrations, with minimal inhibition of T-L activity. G4-1 exerted cytotoxic effects against a variety 
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of solid cancer and MM cell lines, regardless of acquired resistance to BTZ and CFZ. Further structural 
analyses indicated that G4-1 is a reversible, non-covalent inhibitor. As expected from its non-peptide-
based structure, G4-1 displayed much improved in vitro metabolic stability over BTZ or CFZ when 
tested using mouse and human liver microsomes. In a mouse xenograft model of human prostate cancer, 
G4-1 (5 mg/kg, twice-weekly) was effective in suppressing tumor growth with no overt signs of toxicity. 
Additional PK or PD profiles of G4-1 have not yet been published.   
In addition to those described above, there have been several other recent reports of efforts to 
develop non-peptide PIs but further investigations are still needed to validate their mode of interaction 
with the proteasome, their extent of interaction with non-proteasomal targets and their in vivo efficacy. 
While there is also a body of research covering peptide-based non-covalent PIs, such as those described 
by Blackburn et al. [109, 110], it is expected that these compounds will be susceptible to the same rapid, 
often extrahepatic, clearance as existing peptide-based PIs. Peptide-based PIs may also be less likely to 
penetrate poorly-perfused tumors due to either their physiochemical properties or their interactions with 
efflux transporters [111]. Moving forward, significant research efforts will be required to identify non-
peptide PIs which display optimal PK/PD profiles and suitability for clinical use.  
4.4. Application of drug delivery system on proteasome inhibitors 
In improving the PK profiles of the existing PIs, the nanoparticle-based drug delivery systems (NDDS) 
may prove useful by prolonging the circulation time and changing the biodistribution profile, thereby 
enhancing the delivery of PIs to solid cancer tissues and reducing the toxicity in normal tissues. In 
cancer therapy, there exist several examples of successfully applying NDDS: doxorubicin (DoxilTM, 
Janssen, liposomal formulation), irinotecan (Onivyde™, Merrimack Pharmaceuticals, liposomal 
formulation), paclitaxel (Genexol-PM™, Samyang Biopharmaceuticals, polymeric micelle 
formulation; Abraxane™, Celgene, albumin bound nanoparticle) [112].  
For the first-in-class PI drug BTZ, there have been a number of attempts to apply novel NDDS 
and extend the therapeutic utility of BTZ. Polymeric micelle-based formulation of BTZ showed an 
improved tolerability and efficacy against triple negative breast cancer [46]. In another report, BTZ-
containing polymeric micelles were prepared using poly(D,L-lactic-co-glycolic acid) (PLGA) and 
polyethylene glycol with a bone-targeting ligand alendronate. The results showed an extended 
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circulation time as well as enhanced survival and decreased tumor burden in the MM mouse model [47]. 
A similar approach was attempted using PLGA-based nanoparticles conjugated with transferrin as a 
tumor-targeting ligand and the results showed an enhanced delivery of BTZ to pancreatic cancer cells 
[113]. Taking advantage of slightly acidic tumor microenvironment compared to normal tissues, pH-
sensitive polymer carriers were used to design novel delivery options for BTZ (where the drug release 
is triggered under acidic condition) [114-116]. The liposomal nanoparticles were also explored and the 
encapsulation of a BTZ prodrug in the liposomal nanoparticles demonstrated tumor growth suppression 
with reduced toxicity compared to BTZ in the mice carrying MM xenografts [45]. Another report used 
a liposomal BTZ formulation conjugated with NGR peptides and showed improvements in terms of 
toxicity and survival in the orthotopic mouse model of neuroblastoma [117]. Other types of NDDS 
applied to BTZ include hollow mesoporous silica nanospheres [118] and solid-lipid nanoparticles [119]. 
However, the NDDS for BTZ reported so far await further validation and careful examination for their 
clinical translation.  
For CFZ, the NDDS may offer potential benefits of extending the therapeutic utility beyond 
MM, but also of developing an alternative, cyclodextrin-free formulation (the current CFZ formulation 
contains 16-fold molar excess of sulfobutyl ether β-cyclodextrin (Captisol®) to CFZ). During the past 
several years, our laboratory and others have made efforts to develop the NDDS to CFZ. Tethered 
polymer nanoassemblies were prepared for CFZ, but the results showed a modest improvement in the 
cytotoxic effects against human lung cancer cells [120]. Another study examined a dual drug-loaded 
liposomal formulation to deliver CFZ and doxorubicin [121]. The dual drug-loaded liposomes were 
more effective in suppressing tumor growth in a mouse model of MM xenograft than co-administration 
of single drug-loaded liposomes [121]. A more recent report developed CFZ nanoparticles coated with 
neutrophil membranes [122]. The results showed quite promising suppression of early metastasis, but 
the limitations included the multi-step preparatory processes that may not be cost-effective and 
amenable for scale-up [122]. Thus, there is a clear need for novel, cost-effective NDDS which can 
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The proteasome, a multisubunit protease complex, is an anticancer target validated by remarkable 
clinical successes of proteasome inhibitor drugs. Since its fast-track FDA approval in 2003, the first-
in-class proteasome inhibitor drug bortezomib (VelcadeTM) has become a mainstay of multiple 
myeloma (MM) therapy, despite drawbacks including severe neurotoxicity caused by off-target 
interactions with neuronal proteases [123]. In 2012, the second-in-class proteasome inhibitor drug 
carfilzomib (KyprolisTM, CFZ) received an accelerated FDA approval for patients who have 
relapsed/refractory MM after receiving at least two prior therapies including bortezomib. CFZ in 
combination with other immunomodulatory agents such as lenalidomide and dexamethasone 
demonstrated good response profiles and several clinical trials are ongoing for its use as frontline 
therapies [124-126]. Compared to BTZ, CFZ is well tolerated with acceptable toxicity profiles and 
few instances of dose-limiting neurotoxicity, likely due to the selective interactions of its epoxyketone 
pharmacophore with the proteasome target [127]. 
Despite the notable benefits with CFZ, there remains much room for improvement. CFZ is 
practically insoluble in aqueous media and the current formulation contains 60 mg of lyophilized CFZ 
powder with 3,000 mg of sulfobutylether-β-cyclodextrin (Captisol®). Additionally, CFZ is rapidly 
inactivated in vivo; the majority (> 95%) of CFZ is eliminated from systemic circulation within 30 
min following intravenous injection due to its peptide backbone cleavage and epoxide hydrolysis 
[128]. The poor in vivo stability and short half-lives of CFZ have been considered major culprits for 
its lack of efficacy in patients with solid cancers by limiting the access of the active drug to 
proteasome targets within solid tumor tissues [129, 130]. Thus, novel drug delivery strategies that can 
improve solubility, in vivo stability of CFZ and the accessibility of active drug to targeted tumor sites 
may potentially extend its therapeutic benefits in patients with solid cancers. 
Polymeric micelles (PMs) composed of amphiphilic block copolymers have gained much 
attention for their application in drug delivery, especially due to their biocompatibility and utility in 
improving drug solubility and stability in the biological system and achieving passive tumor targeting, 
commonly referred to as enhanced permeability and retention (EPR) effect [131, 132]. In the case of 
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CFZ, it was previously reported that several CFZ-loaded PM formulations composed of 
biodegradable block copolymers poly(ethylene glycol)-poly(caprolactone) (PEG-PCL) displayed 
improved metabolic stability and anticancer efficacy profiles in vitro [133]. Given these results, the 
logical next step was to examine whether these in vitro improvements achieved by CFZ-loaded PM 
formulations would be recapitulated in vivo. 
In this report, we examined the anticancer efficacy and plasma pharmacokinetic (PK) profiles 
of the CFZ-loaded PM formulation (CFZ-PM, composed of PEG-PCL 5-5.5 KDa with deoxycholic 
acid added) in vivo. Despite our previous results showing in vitro metabolic protection with CFZ-PM 
[133], its in vivo performances in terms of anticancer efficacy, plasma PK profiles and proteasome 
inhibition in residual tumor tissues did not show notable improvements over the cyclodextrin (CD)-
based CFZ formulation (CFZ-CD). Careful consideration of these results and confounding factors 
may provide valuable insights into the future efforts to validate the potential of CFZ-based therapy 
for solid cancer and to develop effective CFZ delivery strategies that can be used to treat solid cancers. 
 
2. Materials and Methods 
2.1. Cell lines and reagents 
A human lung adenocarcinoma cell line H460 was obtained from Korean Cell Line Bank (KCLB, Seoul, 
Korea) and maintained according to the KCLB-recommended culture conditions. CFZ was purchased 
from LC laboratories (Woburn, VA, USA). Block polymer PEG-PCL with molecular weight 5-5.5 kDa 
was purchased from Polymer Source (Montreal, QC, Canada). 2-hydroxypropyl-β-cyclodextrin, EDTA, 
chloropropamide, deoxycholic acid (DCA) and formic acid were purchased from Sigma-Aldrich (St. 
Louis, MO, USA). The fluorogenic substrate, N-Succinyl-Leu-Leu-Val-Tyr-7-amino-4-
methylcoumarin (Suc-LLVY-AMC), was purchased from Bachem (Torrance, CA, USA). All solvents 
for HPLC were obtained from Burdick & Jackson Company (Morristown, NJ, USA). 
2.2. Preparation and characterization of CFZ-PM formulation 
The CFZ-PM formulation was prepared using PEG-PCL 5-5.5 KDa with DCA through the thin film 
method as previously described [133]. The particle size distribution and zeta potential values were 
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measured for CFZ-PM or empty PM (prepared without CFZ) using an electrophoretic light scattering 
method (DLS, Zetasizer Nano ZS, Malvern, UK). Critical micelle concentrations (CMCs) of CFZ-PM 
and empty PM were determined using the pyrene I3/ I1 method [134]. Briefly, pyrene solution in acetone 
(2 µM) was added to PM solution in water at varying PM concentrations and left to equilibrate at 37 °C 
overnight. The fluorescence signal intensities of pyrene in the solution were measured at the first (I1 at 
372 nm) and third (I3 at 383 nm) peaks following excitation at 334 nm using a SpectraMax M5 
microplate reader in order to determine the encapsulation of pyrene corresponding to micelle formation 
(SpectraMax M5, Molecular Devices, CA, USA). 
2.3. Anticancer efficacy of CFZ-PM in NOD/SCID mice harboring human lung cancer (H460) 
xenografts 
Animal procedure was performed using the protocol approved by the Seoul National University 
Institutional Animal Care and Use Committee (approval No. SNU-151127-3). NOD/SCID mice were 
obtained from Japan SLC, Inc. (Hamamatsu, Japan). Briefly, H460 cells (3×106 cells/spot) were 
subcutaneously injected into the flank of mice (NOD/SCID, 6-7 weeks old). After the tumor volume 
reached 50 – 150 mm3, the mice were randomized into 6 different treatment groups (n=4-5) as follows; 
CFZ-PM at the dose of 3 or 6 mg/kg, CFZ-CD (complexed with 20% (v/w) 2-hydroxypropyl-β-
cyclodextrin in 10 mM citrate buffer, pH 3) at the dose of 3 or 6 mg/kg, vehicle (10 mM citrate buffer, 
pH 3), and empty PM. Drug was dosed via tail vein injection (two consecutive days/week for 3 weeks). 
Tumor growth was assessed by measuring the short and long diameters of the tumor with a caliper and 
using the following formula: tumor volume (mm3) = 0.5 × (short diameter, mm)2 × (long diameter, mm). 
Mice were sacrificed on day 18 and tumor tissues and whole blood samples were collected for 
proteasome activity assay and immunoblotting analysis. 
2.4. Assessment of proteasome target inhibition/modification in excised xenograft tumor tissues from 
mice that received drug treatment 
In order to assess whether CFZ-PM improved the accessibility of the active drug to tumor tissues, the 
proteasome target inhibition was measured in excised tumor tissues and whole blood samples from 
mice that received drug treatment. Tumor tissues and whole blood samples were collected 48 h after 
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the injection of the respective treatments on the last day of the in vivo efficacy experiment. The excised 
tumor tissues were homogenized with passive lysis buffer (Promega, WI, USA) using a hand-held tissue 
grinder on ice. The homogenates were centrifuged at 3,000g for 20 min at 4°C and the resulting 
supernatant was used for proteasome activity assay and immunoblotting analysis. The proteasome 
activity was determined by monitoring the cleavage rate of fluorescent 7-amino-4-methylcoumarine 
(AMC) from Suc-LLVY-AMC. Briefly, lysates of excised tumor tissues (10 µg of total protein) or 
whole blood (1 µL) were incubated with Suc-LLVY-AMC (100 µM dissolved in 20 mM Tris-Cl buffer 
(pH 8.0) containing 500 µM EDTA). Fluorescence signals of liberated AMC were monitored for a 
period of 60 min using excitation and emission wavelengths of 360 and 460 nm on a SpectraMax M5 
microplate reader (Molecular Devices, CA, USA). 
Since CFZ irreversibly inhibits the proteasome via covalent modification, the presence of covalently 
modified catalytic subunit β5 can also be used to assess the extent of the proteasome inhibition. Briefly, 
tumor tissue lysates (10 µg of total protein) were resolved using 12.5% SDS-PAGE and transferred 
onto a PVDF membrane (Bio-Rad Laboratories). Membranes were blocked in 5% milk in Tris-buffered 
saline containing 0.05% Tween-20 (TBST) and probed with the following antibodies; for β5 (dilution 
1:1000, Abcam) and β-actin (dilution 1:1000, Cell Signaling). Membranes were washed with TBST 
and probed with the corresponding secondary antibodies conjugated with horseradish peroxidase. 
Bound antibodies were visualized using an enhanced chemiluminescence substrate (Thermo Fisher 
Scientific). 
2.5. Assessment of plasma PK profiles of CFZ-PM in mice 
PK studies in mice were carried out following the protocol approved by the Seoul National University 
Institutional Animal Care and Use Committee (approval No. SNU-160512-5). The CFZ-PM and CFZ-
CD were injected via tail vein into ICR mice obtained from Samtako (Gyeonggido, Korea) at doses of 
3 or 6 mg/kg (n=4-5 per group), respectively. At the pre-determined time points (2, 5, 20, 60, 120, 360, 
600 and 1,440 min), whole blood samples were collected from the retro-orbital plexus of the mice using 
microhematocrit tubes. To minimize blood loss due to sampling, approximately 50 µL of whole blood 
was drawn at each sampling time and individual mice did not have more than 6 times of blood sampling. 
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Plasma samples (20 µL) separated from whole blood were quenched with acetonitrile (60 µL) 
containing chlorpropamide (2 µg/mL, an internal standard) and mixed by vortexing for 15 min. After 
the mixture was centrifuged at 9,000 g for 15 min at 4°C, the concentration of CFZ in the supernatant 
was measured using an HPLC interfaced with mass spectrometry (Shimadzu LCMS-8050). Briefly, 10 
µL of the resulting supernatant was injected and separation of CFZ and chlorpropamide was achieved 
using a Phenomenex C18 column and the mobile phase composed of H2O:acetonitrile (40:60, v/v) 
containing 0.1% formic acid (flow rate = 0.35 mL/min). CFZ and chlorpropamide were detected in the 
ESI mode (positive ion mode, CFZ: 720.20→100.15 m/z; chlopropamide: 277.05→175.10 m/z). The 
detailed report on analytical conditions and assay validation parameters including accuracy and 
precision is currently in preparation. PK parameters were calculated using non-compartmental methods 
(WinNonLin version 5.0.1, Pharsight). 
2.6. Statistical analyses 
The results were expressed as the mean with standard deviation. Statistical significance between groups 
was determined using ANOVA followed by Dunnett’s or Tukey’s post hoc test (GraphPad Prism, 




3.1. Physicochemical properties of CFZ-PM 
The particle size distribution and zeta potential of CFZ-PM and empty drug-free PM were determined 
using dynamic light scattering. The mean diameters of CFZ-PM and empty PM were comparable (56.0 
± 6.1 vs 41.2 ± 5.7 nm) and so were zeta potential values (-0.1 ± 0.4 vs -0.5 ± 0.3 mV) (Table 1). These 
results indicated that both size distribution and zeta potential were not substantially altered by CFZ drug 
loading. In addition, particle sizes did not show substantial changes in cell culture media containing 
fetal bovine serum compared to phosphate-buffered saline (data not shown). These results suggest that 
PEGylation of micelles may have decreased the tendency for nanoparticles to aggregate. The critical 
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micelle concentration (CMC) values measured by fluorescence spectrophotometry with pyrene were 
also comparable between empty PM and CFZ-PM with 0.18 and 0.14 mg/mL, respectively (Table 1). 
Table 1. Physicochemical characterization of drug-free and carfilzomib (CFZ)-loaded polymeric 
micelles (PM). 
Group Size (nm) Zeta potential (mV) CMC (mg/mL) 
Drug-free PM 41.2 ± 5.7 -0.5 ± 0.3 0.18 
CFZ-PM 56.0 ± 6.1 -1.0 ± 0.4 0.14 
Data are shown as means ± S.D. (n=3). CMC, critical micelle concentration 
3.2. In vivo anticancer efficacy of CFZ-PM in H460 xenograft mice  
The doses and dosing schedules of CFZ-PM and CFZ-CD (3 or 6 mg/kg, intravenous administration on 
two consecutive days per week) were based on clinically used regimens and available information in 
the literature [135]. The tumor size was substantially smaller in the groups that received CFZ-PM or 
CFZ-CD than in the control groups that received empty PM or vehicle only, but no difference was 
observed between the groups that received CFZ-PM and CFZ-CD at the dose of 3 mg/kg (Fig 1A). It 
was unable to compare tumor growth suppression of CFZ-PM to that of CFZ-CD at the dose of 6 mg/kg 
since 4 out of 6 mice that received 6 mg/kg of CFZ-CD died during the treatment period. The mice that 
received 6 mg/kg of CFZ-PM survived with no sign of substantial toxicity, at least based on body weight 
changes (Fig 1D). The tumor growth suppression by CFZ-PM was not however dose-dependent; tumor 
growth curves for 3 and 6 mg/kg doses overlapped and weights of excised tumors for both doses were 
similar (Figs 1B and 1C).  
3.3. Proteasome inhibition in post-treatment xenograft tumor tissues and whole blood samples 
collected from mice that received CFZ-PM or CFZ-CD 
In order to probe possible reasons for no enhancement of anticancer efficacy with CFZ-PM over CFZ-
CD, we compared the extent of proteasome inhibition in the excised xenograft tumor tissues and whole 
blood samples collected from the xenograft mice receiving different drug treatments (collected 48 h 
following the last injection). In the groups that received CFZ-PM (3 or 6 mg/kg) or CFZ-CD (3 mg/kg), 
the inhibition of the proteasome activity in tumor lysates was modest (and not reaching statistical  
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Figure 1. Effects of polymeric micelle formulation containing carfilzomib (CFZ-PM) vs cyclodextrin-
based carfilzomib formulation (CFZ-CD) on tumor growth in H460 xenograft mice. NOD/SCID mice 
harboring H460 xenograft tumors were randomized to 5 different groups and received respective 
intravenous injections on two consecutive days per week; CFZ-PM at the dose of 3 (□) or 6 (■) mg/kg, 
CFZ-CD at the dose of 3 (△) mg/kg, vehicle (citrate buffer ●) and empty PM (dissolved in saline ○). 
The upper arrow symbol (↑) indicates the day of drug injection. (A) Tumor growth curves. (B, C) 
Weights and images of excised tumor tissues on day 18. (D) Body weights. Data are shown as means 
± S.D. (n=4-5). *, p < 0.05 vs. vehicle control using ANOVA followed by Dunnett’s post hoc test. 
 
significance), with more than 50% of the activity remaining relative to the control group (Fig 2A). It 
should be noted that these results were obtained from the residual tumor tissues collected 48 h after last 
injection of the respective treatments. Thus, the measured proteasome activity in tumor lysates may 
represent that from tumor cells where active CFZ did not reach. Alternatively, the measured proteasome 
activity may come from the recovery following the initial inhibition. For instance, the previous report 
by Demo et al. [31] showed that the proteasome activity in major organs can substantially recover 24 h 
after intravenous injection of the single CFZ dose of 5 mg/kg. However, these results differ from those 
obtained by other investigators. With a repeated dosing schedule (clinically used and same as our 
current study), the proteasome activity in patients displayed only a minimal recovery [136]. The slow 
recovery of proteasome activity is also in line with rather slow proteasome de novo biogenesis rates 
taking at least several days [137-140]. Given the irreversible nature of proteasome inhibition by CFZ 
and a relatively long time for de novo proteasome biogenesis to replace the covalently modified 
proteasomes, the observed proteasome activity in residual xenograft tissues is unlikely from the 
recovery following initial inhibition [141]. In contrast, the proteasome activities in whole blood samples 
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collected 48 h after the last injection of the respective treatments showed an almost complete inhibition 
in all three tested groups, CFZ-PM (3 or 6 mg/kg) and CFZ-CD (3 mg/kg) (Fig 2B, p < 0.001, each 
treatment different from the control). 
 
Figure 2. Proteasome activities in the post-treatment tumor tissue lysates (A) and whole blood samples 
(B) collected from H460 xenograft mice that received the intravenous injections of polymeric micelle 
formulation containing carfilzomib (CFZ-PM) or cyclodextrin-based carfilzomib formulation (CFZ-
CD). The tumor tissues and whole blood samples were collected 48 h after the last injection of the 
respective treatments. Proteasome activities in tumor tissue lysates or whole blood lysates were assessed 
by measuring the cleavage rate of the fluorogenic substrate Suc-LLVY-AMC. *, p < 0.001 vs. all other 
groups using ANOVA followed by Dunnett’s post hoc test. 
 
In addition to measuring post-treatment proteasome activities, we also probed the extent of CFZ-
induced covalent modification of the major proteasome catalytic subunit β5. This assay takes advantage 
of the altered electrophoretic mobility of the covalently modified β5 protein by CFZ as previously 
described [142]. The band of the positive control (tumor lysates incubated with 50 nM CFZ for 2 h in 
vitro) showed a mobility shift compared to the negative control (tumor lysates incubated with the 
vehicle DMSO for 2 h) (Fig 3). No detectable β5 band shift was observed in the post-treatment tumor 
lysates collected 48 h after the last drug treatment in either CFZ-PM or CFZ-CD groups. Altogether, 
these results suggest that CFZ-PM did not enhance the access of active CFZ to cancer cells in xenograft 
tumors and the extent of proteasome inhibition in vivo.  
 
Figure 3. Immunoblotting analyses showing that the proteasome catalytic subunit β5, a primary target 
of carfilzomib remains unchanged in post-treatment tumor tissue lysates collected from the xenograft 
mice that received different treatments. (CFZ-CD: cyclodextrin-based carfilzomib formulation; CFZ-
PM: polymeric micelle formulation containing carfilzomib) The tumor tissues were collected 48 h after 
the last injection of the respective treatments. 
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3.4. Comparison of plasma PK profiles of CFZ-PM and CFZ-CD in ICR mice 
Given that CFZ-PM did not suppress tumor growth more effectively than CFZ-CD (Fig 2), it 
was examined whether the plasma PK profiles differ between CFZ-PM and CFZ-CD. Following the 
intravenous injection of CFZ-PM or CFZ-CD to ICR mice, the plasma concentration-time curves for 
both groups displayed a rapid decline. During early time points (up to 2 h), the mice that received CFZ-
PM (either 3 or 6 mg/kg) showed higher drug concentrations than those that received CFZ-CD (Fig 4). 
However, this trend was reversed in later time points (6, 12 and 24 h after injection); the mice that 
received CFZ-PM injection (3 or 6 mg/kg) showed lower CFZ concentrations in plasma than those that 
received CFZ-CD. 
 
Figure 4. Plasma concentration-time profiles of carfilzomib after the intravenous administration of 
polymeric micelle formulation containing carfilzomib (CFZ-PM) or cyclodextrin-based carfilzomib 
formulation (CFZ-CD) to mice (A, 3 mg/kg and B, 6 mg/kg). Data are shown as means ± S.D. (n=4-5). 
The inset figures show the plasma concentration-time profiles up to 2 h. 
 
Table 2. Pharmacokinetic parameters of carfilzomib after the intravenous administration of polymeric 
micelle formulation containing carfilzomib (CFZ-PM) and cyclodextrin-based carfilzomib formulation 
(CFZ-CD) to ICR mice. 
Pharmacokinetic Parameters 
CFZ-PM  CFZ-CD 
3 mg/kg 6 mg/kg  3 mg/kg 6 mg/kg 
AUC0-2h (nmol×min/mL) 38.6 ± 1.2 118.1 ± 25.3  33.3 ± 7.7 55.2 ± 21.1 
AUC0-24h (nmol×min/mL) 39.8 ± 0.8 121.4 ± 27.2  35.4 ± 8.0 58.8 ± 21.8 
AUCINF (nmol×min/mL) 39.9 ± 0.8 121.8 ± 27.4  36.4 ± 8.0 62.6 ± 22.9 
CL (mL/min/kg) 105 ± 2 71 ± 15  119 ± 29 152 ± 71* 
Data are shown as means ± S.D. (n=4-5). AUC0-2h, Area under the plasma concentration-time curve (AUC) from 
time 0 to 2 h; AUC0-24h, AUC from time 0 to 24 h; AUCINF, AUC extrapolated to infinity; CL, clearance. *, p < 
0.05 vs. all other groups using ANOVA followed by Tukey’s post hoc test. 
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For detailed comparison, the PK parameters were obtained using non-compartmental methods (Table 
2). As expected from the rapid initial decline in the plasma concentration-time curves, the AUC0-2h 
values accounted for approximately 96.7% and 97.0% of the AUCINF values in the CFZ-PM groups at 
the doses of 3 and 6 mg/kg, respectively. In the case of the CFZ-CD groups, the AUC0-2h values 
accounted for approximately 91.4% and 88.1% of the AUCINF values at the doses of 3 and 6 mg/kg, 
respectively. The CL values of CFZ in all four groups exceeded the average hepatic blood flow in mice, 
suggesting substantial extrahepatic metabolism of CFZ. These results are in line with the previous 
reports in rats and humans [128, 130]. The systemic exposure of CFZ-PM and CFZ-CD at the dose of 
3 mg/kg appeared to be comparable based on the similar AUCINF and CL values between the two groups. 
When the AUCINF values of 3 and 6 mg/kg doses were compared, the CFZ-PM group displayed 
approximately 3-fold increases (39.9 ± 0.8 vs 121.8 ± 27.4) while the CFZ-CD group displayed 
approximately 1.7-fold increases (36.4 ± 8.0 vs 62.6 ± 22.9). These differences in the AUCINF values 




The proteasome is well accepted as a critical player in several traditional hallmarks of cancer, defined 
by Hanahan and Weinberg [143]. More recently, proteotoxic stress triggered by imbalances in protein 
homeostasis has been annotated as another hallmark of cancer [144]. In this regard, CFZ with improved 
efficacy and safety profiles merits further investigations to extend its therapeutic utility beyond MM. 
In particular, recent reports suggested that certain solid cancers render proteasome addiction as 
vulnerability, thereby a potential target for therapeutic interventions. Using genome-wide siRNA 
screening, the knockdown of proteasome genes was found to cause lethality in basal-like triple-negative 
breast cancer cells [145]. This particular study examined the effectiveness of bortezomib administered 
via different dosing routes in suppressing in vivo tumor growth and metastasis. Only intratumoral 
injection, but neither intraperitoneal nor intravenous route, displayed an efficient proteasome inhibition 
associated with enhanced anticancer efficacy [145]. An early report with bortezomib also indicated that 
intratumoral injection of the drug leads to an effective proteasome inhibition and growth suppression 
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in mice harboring prostate cancer xenografts [146]. Altogether, these findings provide an impetus to 
develop novel delivery strategies that can effectively target proteasomes in solid cancer tissues and 
validate the potential of CFZ-based therapy for solid cancer patients. 
Previously, we developed several CFZ-loaded PM formulations displaying improved metabolic 
stability and anticancer efficacy in vitro [133]. In this study, we investigated in vivo anticancer efficacy 
and PK profiles of CFZ-PM (CFZ-loaded PEG-PCL 5-5.5 KDa with DCA) in mice. In the tumor 
xenograft model, CFZ-PM did not show substantial improvements in the anticancer efficacy and 
proteasome inhibition at the tumor sites over CFZ-CD (Figs 2 and 3). In addition, the plasma PK profiles 
of CFZ-PM were for the most part comparable to those of CFZ-CD at the dose of 3 mg/kg except 
showing slightly higher drug concentrations at early time points (Fig 4). These results indicated an 
incomplete proteasome inhibition in the post-treatment tumor tissues collected from H460 xenograft 
mice 48 h after the last injection of CFZ-PM (Figs 2 and 3). In further probing possible reasons for the 
lack of improvements with CFZ-PM over CFZ-CD, it would be important to examine whether the 
xenograft model employed in the current study allowed for sufficient passive targeting effect. The 
particle size distribution of CFZ-PM (56.0 ± 6.1 nm, Table 1) is sufficiently small to pass through the 
pore size of vascular membranes (60 ~ 100 nm) [147, 148]. However, these results suggest that CFZ-
PM was not more effective in providing the access of active CFZ into tumor sites than CFZ-CD. It is 
increasingly recognized that tumor types, tumor vascular heterogeneity, abnormal tumor blood vessels 
or high interstitial fluid pressure may influence the access of chemotherapy to cancer cells [149, 150]. 
To overcome such variability, various pharmacological and physical strategies including focal radiation 
and sonoporation have been exploited in the field [151-153]. It would be important to obtain more 
detailed biodistribution data and to consider combining approaches to improve tumoral penetration of 
active CFZ in future investigations. 
The extent and rate of CFZ release from CFZ-PM in vivo may also be a factor influencing 
anticancer efficacy. The plasma PK profiles of CFZ-PM after a single intravenous administration 
displayed higher drug concentrations during the initial phase (up to 2 h) than those of CFZ-CD at the 
dose levels of both 3 and 6 mg/kg (Fig 4). When the plasma PK parameters were compared, mice that 
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received CFZ-PM (6 mg/kg) displayed a greater systemic exposure and a slower CFZ clearance than 
those that received CFZ-CD (6 mg/kg) (Table 2). However, the systemic toxicity appeared to be more 
severe in xenograft mice treated with CFZ-CD (6 mg/kg) than those treated with CFZ-PM (6 mg/kg); 
four out of six mice receiving 6 mg/kg repeated doses of CFZ-CD died. Although these results need to 
be interpreted with caution due to the small sample size, these results suggest that CFZ-PM may have 
the potential to increase maximum tolerated dose levels and possibly CFZ release kinetics and 
biodistribution profiles different from CFZ-CD. Given the relatively low drug loading efficiency (2.3%) 
of the current CFZ-PM [133], the initial micelle concentrations (upon immediate dilution of the CFZ-
PM 3 mg/kg dose in an average mouse blood volume of approximately 2 mL) are estimated to be well 
above the measured CMC value (0.14 mg/mL, Table 1). However, as polymers are cleared from blood, 
micelle concentration will decrease and micelles could degrade and release CFZ. Thus, it might be 
necessary to explore polymer-based nanoparticles stabilized with various structural/functional 
modifications [132, 147]. For the docetaxel-loaded PM formulation composed of the same block 
copolymer, PEG-b-PCL, the CMC value of 0.02 mg/mL was reported in in vitro conditions [154]. Thus, 
it may be feasible to lower CMC values for CFZ-loaded PM formulations by carefully optimizing 
various factors (e.g., drug-to-polymer ratios, addition of excipients stabilizing hydrophobic cores) using 
the current block copolymer or by using different types of block copolymers. 
In summary, the results in this study showed that the current CFZ-PM does not enhance anti-
cancer efficacy in vivo. Careful consideration of these results and confounding factors may provide 
valuable insights into the future efforts to validate the potential of CFZ-based therapy for solid cancer 








Expanding Therapeutic Utility of Carfilzomib for Breast Cancer 







* The work from Chapter II is currently under revision in Journal of Controlled 
Release (Manuscript number: JCR-D-18-01200).   
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1. Introduction 
Breast cancer is ranked first in the incidence of disease and second in cancer-related deaths in women 
worldwide [1, 2]. Among different subtypes of breast cancer, triple-negative breast cancer (TNBC), 
which lacks the expression of estrogen receptor, progesterone receptor, and human epidermal growth 
factor receptor 2 (HER2), is notorious for its aggressive behavior and resistance to endocrine and anti-
HER2 therapies (e.g., tamoxifen, trastuzumab) [3, 4]. Thus, novel and effective therapies for TNBC are 
urgently needed. A growing body of preclinical evidence supports that the proteasome is an effective 
therapeutic target against breast cancers including TNBC [5, 6]. Bortezomib, the first-in-class 
proteasome inhibitor, reversibly inhibits the proteasome with its boronic acid pharmacophore. While 
bortezomib has shown remarkable successes in multiple myeloma therapy, it has brought only marginal 
therapeutic benefits to patients with solid cancers including breast cancer [7]. The lack of clinical 
efficacy of bortezomib is attributed in part to its poor penetration into the targeted solid tumor tissues 
and the narrow therapeutic window due to dose-limiting toxicities arising from proteasomal inhibition 
in normal tissues and off-target interactions with non-proteasomal targets [5, 8].  
Carfilzomib (CFZ, Kyprolis®) is the second-in-class proteasome inhibitor and has received the 
FDA approval a decade after the approval of bortezomib. Unlike bortezomib, CFZ covalently and 
irreversibly inhibits the proteasome with its epoxyketone pharmacophore and displays minimal 
interactions with non-proteasomal targets, thereby improving safety profiles over bortezomib [9]. Due 
to the poor solubility of CFZ (log P = 4.13, ~ 10 µM in PBS [10]), the current injectable formulation of 
CFZ contains 16-fold molar excess of sulfobutyl ether β-cyclodextrin (Captisol®) as a solubilizer. When 
administered as the current cyclodextrin (CD)-based formulation, CFZ has a very short circulation time 
(plasma half-lives of 0.5 – 1 h in humans and preclinical species) due to the extensive hepatic and extra-
hepatic metabolism and wide tissue distribution [11]. As an alternative formulation, previous studies 
have surveyed the feasibility of CFZ nanoformulations including liposomes, polymer micelles, tethered 
polymer nanoassemblies, and neutrophil membrane-coated nanoparticles [12-15]. The shortcomings of 
these approaches however include the low drug loading efficiency, burst release of the drug in blood 
circulation, and no-to-marginal improvement in in vivo anticancer efficacy. Thus, there is a clear need 
 34 
for a new nanoformulation of CFZ with improved pharmacokinetic (PK) and biodistribution (BD) 
profiles as well as pharmacodynamics, such as anticancer efficacy and proteasome target modulation.  
To develop a cost-effective nanoformulation with an improved circulation time and anticancer 
efficacy in vivo, we designed a CD-free, nanocrystal (NC)-based formulation of CFZ. NC formulations 
exploit poor water solubility of anticancer drugs to produce injectable nanoparticles with a high drug 
content [16-18]. NCs with sufficiently high lattice energy can circulate for a prolonged period and may 
gain selective access to solid tumors via leaky vasculature. To facilitate favorable interactions of NCs 
with cancer cells (thereby enhancing the delivery of NCs to cancer cells), the surface of NCs can be 
modified with various molecules. In particular, albumin has gained considerable interest as a potential 
surface modifier, due to low toxicity, biocompatibility, and the ability to reduce interactions with 
phagocytes in the reticuloendothelial system (RES) [19-21]. Moreover, albumin can interact with 
cancer cells based on its increased use as an energy source in rapidly proliferating cancer cells [22]. It 
has been reported that nano-albumin-bound-drugs (nab-drugs) can aid drug permeation across tumor 
vessels [23, 24]. Albumin-bound paclitaxel (nab-paclitaxel) displayed promising efficacy and safety 
profiles in patients with breast cancers including TNBC [25]. Although the exact mechanisms by which 
nab-drugs reach cancer cells are not fully understood, it is suggested that albumin facilitates the 
movement across the endothelial cell membrane by binding to the gp60 receptor and sequentially 
interacting with other albumin-binding proteins such as SPARC (Secreted Protein Acidic and Rich in 
Cysteine) abundantly expressed in and near cancer cells [26]. Importantly, our previous studies support 
that albumin coating helps deliver paclitaxel and docetaxel NCs to solid tumors through the interaction 
with those albumin-binding proteins [27, 28]. 
In this study, we examined whether NCs with albumin coating could enhance the delivery of 
CFZ to breast cancers. Using albumin-coated CFZ NCs (CFZ-alb NC), we observed that CFZ-alb NC 
enhanced cytotoxic effects in breast cancer cell lines and tumor growth suppression in a murine 4T1 
orthotopic breast cancer model, compared to the CD-based formulation of CFZ (CFZ-CD). We also 
observed the improved BD profiles of CFZ-alb NC in 4T1 orthotopic breast cancer model and 
investigated potential involvement of SPARC in the enhanced tumoral accumulation of CFZ-alb NC.  
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2. Material and methods 
2.1. Materials 
CFZ was purchased from Shenzhen Chemical Co. Ltd. (Shanghai, China). Pluronic F127 (F127) was a 
gift from BASF (New York, NY, USA). Human serum albumin (HSA; ≥ 96% purity assessed by 
agarose gel electrophoresis, Cat. No. A1653) and (2-hydroxypropyl)-β-cyclodextrin were from Sigma-
Aldrich (St. Louis, MO, USA). All other reagents were from Thermo Fisher Scientific (Waltham, MA, 
USA). 
2.2. Preparation of CFZ-alb NC 
CFZ-alb NC was prepared by crystallizing CFZ in the presence of F127 and coating the resulting CFZ-
NC with HSA, as reported previously [28]. Briefly, 6 mg of CFZ and 48 mg of F127 were dissolved in 
a mixture of 3 mL of chloroform and 1 mL of methanol and dried in a round-bottom flask by rotary 
evaporation at 40 ˚C for 10 min. The dry drug-polymer film was hydrated with 6 mL of water and 
sonicated in a water bath for 10 s. The NC suspension was further probe-sonicated for 5 min with an 
amplitude of 40% and a 4:1 duty cycle every 5 s in an ice bath. Subsequently, the suspension was 
incubated with 48 mg of HSA for 24 h at room temperature on a rotating shaker. Excess surfactant and 
albumin were removed by centrifugation at 135,700 g for 15 min at 4 ˚C. 
Optionally, CFZ-alb NC was fluorescently labeled by adding rhodamine B as 0.1 mg/mL 
aqueous solution during the film hydration step. The rhodamine B-labeled CFZ-alb NC was called 
*CFZ-alb NC. To quantify the incorporated rhodamine B, the fluorescence intensity (λex/λem= 540 
nm/625 nm) of a known amount of CFZ-alb NC dissolved in acetonitrile (ACN) was measured with a 
SpectraMax M3 microplate reader (Molecular Devices, CA, USA). Most in vitro studies were 
performed with freshly prepared CFZ-alb NC. For in vivo studies, CFZ-alb NC was lyophilized with 
trehalose as a cryoprotectant (CFZ-alb NC:trehalose = 1:5 (w/w)) (Fig. S1). The lyophilized product of 
CFZ-alb NC was dissolved in PBS before administration. The concentration of trehalose in the dosing 
solution (containing 0.8 mg/ml of CFZ) was estimated to be around 4.3 mOsm/L, which is unlikely to 
compromise the isotonicity (approximately 300 mOsm/L). 
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2.3. Characterization of CFZ-alb NC  
2.3.1. Size, surface charge, and morphology 
The size and surface charge of CFZ-alb NC diluted in phosphate buffer (1 mM, pH 7.4) were measured 
with a Zetasizer Nano-ZS90 (Malvern Instruments, Westborough, MA, USA). The morphology of 
CFZ-alb NC was examined with a FEI Tecnai G2 20 Transmission Electron Microscope  (FEI Company, 
Hillsboro, OR, USA) at 200 keV. Samples were mounted on a 400-mesh Cu grid with Formvar/carbon 
supporting film, followed by negative staining with 1% uranyl acetate. Images were captured with a 
SIA L3-C2 megapixel CCD camera (Scientific Instruments and Application, Duluth, GA, USA). The 
length of CFZ-alb NC was analyzed from TEM images with ImageJ (National Institutes of Health, 
Bethesda, MD, USA). 
2.3.2. Powder X-ray diffraction (PXRD) 
CFZ and CFZ-alb NC were analyzed with a Rigaku SmartLab diffractometer (Rigaku Americas, The 
Woodlands, TX, USA) equipped with a Cu-Kα radiation source. The powder samples were placed on 
glass holder, and diffraction patterns were obtained from 5 to 40° 2θ at a scan speed of 4° per min and 
a step size of 0.02°. The voltage and current used were 40 kV and 44 mA, respectively. 
2.3.3. Contents of CFZ and albumin in CFZ-alb NC 
The CFZ content in CFZ-alb NC was determined by HPLC. CFZ-alb NC with a pre-measured mass 
was dissolved in a 50:50 mixture of ACN and water and filtered with 0.45 µm syringe filter. HPLC was 
performed with an Agilent 1100 HPLC system (Agilent, Palo Alto, CA, USA), equipped with Ascentis 
C18 column (25 cm × 4.6 mm, particle size: 5 µm). The column was initially equilibrated with 40% of 
ACN, followed by a linear gradient of ACN from 40% to 80% over 10 min and from 80% to 40% over 
the next 10 min at a flow rate of 0.7 mL/min. CFZ was detected with a UV detector at a wavelength of 
210 nm. 
The albumin content in CFZ-alb NC was quantified with SDS-PAGE. CFZ-alb NC with a 
known mass or albumin standard solutions were mixed with 4× Laemmli sample buffer and heated at 
95 °C for 5 min to separate albumin from CFZ-alb NC. The samples were resolved in a 12% 
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polyacrylamide gel and stained with QC Colloidal Coomassie Stain (Bio-Rad, Hercules, CA, USA). 
The stained gel was imaged with Azure C300 (Azure Biosystems, Dublin, CA, USA), and albumin 
bands were subjected to densitometric analysis using the AzureSpot Analysis Software (Azure 
Biosystems, Dublin, CA, USA). The albumin content was determined by comparing the band intensity 
of CFZ-alb NC and albumin standards. 
2.4. Stability of CFZ-alb NC 
2.4.1. Physical stability 
To predict the physical stability of CFZ-alb NC, we resorted to a linear relationship between the number 
of particles and light scattering intensity [29]. The derived count rate (i.e., absolute light scattering) of 
CFZ-alb NC suspension with a concentration equivalent to CFZ 7.2 – 72 µg/mL was measured in 
phosphate-buffered saline (PBS) or undiluted fetal bovine serum (FBS) at 37 ˚C over 24 h with a 
Zetasizer Nano-ZS90 (Malvern Instruments, Westborough, MA, USA). The derived count rate of FBS 
was subtracted from each measurement made in FBS. In a separate experiment, the dissolution of CFZ-
alb NC in FBS was monitored by measuring the count rate continuously over 20 min at the final 
concentration equivalent to 7.2 or 30 µg/mL of CFZ. Measurements were made twice every two seconds 
at the measurement position of 4.65 nm and with an attenuator setting of 10. 
2.4.2. In vitro metabolic stability 
To compare the in vitro metabolic stability in CFZ formulations (CFZ solution, CFZ dissolved in 
dimethyl sulfoxide (DMSO); CFZ-CD, CFZ dissolved in 10 mM citrate buffer (pH 3.1) containing 20% 
(w/v) 2-hydroxypropyl-β-cyclodextrin); and CFZ-alb NC dissolved in PBS), the whole blood and the 
liver were collected from a male Sprague Dawley rat. The whole blood was treated with heparin (25 
IU/mL) and kept on ice until the assay was performed. The isolated liver was washed and homogenized 
in ice-cold PBS (pH 7.4, a 1:5 ratio of liver weight (g) to PBS volume (mL)). Each of CFZ formulations 
(4 µL) was added to the whole blood (396 µL) or liver homogenates (396 µL) to result in the final CFZ 
concentration equivalent to 1 µM. A reaction mixture (40 µL) was taken at 0, 5, 10, 30, and 60 min at 
37 °C, and snap-frozen in liquid nitrogen until the measurements of the remaining CFZ concentration. 
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2.5. Cell cultures and treatments  
Human breast cancer cell lines (MDA-MB-231, MCF-7, HCC1943, and HCC1937) were obtained from 
Korean Cell Line Bank (KCLB, Seoul, Korea). Mouse breast cancer cell line 4T1 was purchased from 
ATCC (Manassas, VA, USA). All cell lines were maintained in RPMI-1640 medium supplemented 
with 10% FBS and penicillin-streptomycin (100 IU/mL-100 µg/mL) at 37 °C in a humidified incubator 
operating at 5% CO2. 
2.5.1. Cellular uptake study for rhodamine B-labeled CFZ-alb NC (*CFZ-alb NC)   
Cells were seeded in a 35 mm glass bottom dish (MatTak, Ashland, MA, USA) at a density of 50,000 
cells per dish. After 24 h, the medium was replaced with fresh medium, and the cells were incubated 
with *CFZ-alb NC equivalent to 30 µg/mL CFZ or free rhodamine B solution at a comparable level for 
2 h in complete medium. After washing twice with PBS, the cells were fixed with 4% paraformaldehyde 
in PBS for 10 min. Following nuclear staining with Hoechst 33342 (2 µg/mL; Cat. No. H1399), cells 
were imaged with a Nikon A1R confocal microscope (Nikon America Inc., Melville, NY, USA). 
Hoechst 33342 and *CFZ-alb NC or free rhodamine B were detected with λex/λem of 407 nm/425 – 475 
nm and 561 nm/570 – 620 nm, respectively. For quantitative analysis, cells were prepared in the same 
manner and analyzed with an Accuri C6 flow cytometer (BD Biosciences, San Jose, CA, USA). At 
least 10,000 gated events were acquired, and FL-2 channel (λex/λem 488 nm/585 nm) was monitored to 
determine the cellular level of rhodamine B. 
2.5.2. Cell viability assay 
Cancer cells were seeded on 96-well plates (4T1, 2000 cells/well; MDA-MB-231 and MCF-7, 5000 
cells/well; HCC1640, HCC1937, and U87MG, 8000 cells/well) 24 h prior to drug treatment. For the 
continuous drug treatment condition, cells were continuously exposed to CFZ solution or CFZ-alb NC 
for 72 h. For the pulse treatment condition, cells were treated with CFZ solution or CFZ-alb NC for 2 
h, then washed twice with PBS, and grown in drug-free media for 72 h. Viable cells were measured 
with the CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega, Madison, WI, USA) 
using Synergy HT plate reader (BioTek, Winooski, VT, USA). 
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2.6. Animal experiments 
BALB/c mice (female, 5 – 6 weeks of age, 19 – 21 g), ICR mice (male, 8 weeks of age, 35 – 38 g), and 
Sprague Dawley rats (male, 8 weeks of age, 250 – 260 g) were obtained from Nara Biotech Co., Ltd. 
(Seoul, Korea) or Envigo (Indianapolis, IN, USA), and were acclimatized at the animal research facility 
in Seoul National University (SNU) or Purdue University (PU) for at least one week. All animal 
experiments were performed in accordance with the protocols approved by the Institutional Animal 
Care and Use Committee of SNU and PU (SNU-161205-2-1, SNU-170424-2-1, and PU-1503001212). 
2.6.1. In vivo anticancer activity  
To establish an orthotopic breast cancer mouse model, 4T1 cells (1.5 × 105 cells suspended in 50 µL of 
complete media) were inoculated into the inguinal mammary fat pad on both left and right sides of 
BALB/c mice (on day 0). When the palpable knob with a similar size appeared on day 4, the mice 
bearing 4T1 xenograft were randomly assigned to different groups (n= 5 – 6 per group) as follows: 
vehicle only group (10 mM citrate buffer (pH 3.1)), CFZ-CD at a dose of 3 mg CFZ/kg, and CFZ-alb 
NC at a dose of 3 mg CFZ/kg. The drug was administered two consecutive days a week for three weeks 
via tail vein injection. Tumor size was measured using a digital caliper; tumor volume = 
length×(width)2/2. The body weight of mice was monitored every 2 – 3 days until day 22. Whole blood 
samples and harvested major organs were snap-frozen and stored at -80 °C until analysis or fixed in 4% 
paraformaldehyde and embedded in paraffin for histological examination. 
2.6.2. Plasma pharmacokinetic study 
CFZ-alb NC and CFZ-CD were injected via tail vein into ICR mice at the dose of 3 mg/kg (n = 3 – 4 
per group). At the pre-determined time points (2, 5, 20, 60, 120, 360, 600, and 1,440 min), blood 
samples (10 – 20 µL) were collected from the retro-orbital plexus of the mice using microhematocrit 
tubes. The detailed analytical conditions and assay validation parameters were previously reported [30]. 
PK parameters were calculated by non-compartmental method using WinNonlin software (Pharsight 
Corp., Version 5.0.1). 
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2.6.3. Biodistribution study 
CFZ-alb NC and CFZ-CD were injected via tail vein into BALB/c mice harboring orthotopic xenografts 
(described in 2.6.1.) at an equivalent dose of 3 mg/kg when the tumor size became approximately 200 
– 300 mm3. After 0.5, 2, and 6 h, the mice were anesthetized with isoflurane/oxygen mixture (3 – 5%:95 
– 97%; v/v). At least 800 µL of blood was collected with a heparinized syringe via cardiac puncture. 
Tumor and major organs were harvested, weighed, and snap-frozen until analysis. To measure the CFZ 
amount accumulated in tissues, the tissue homogenates were prepared on ice by adding the following 
proportion of PBS; 0.2 g tissue per mL PBS for all tissues except the lung (0.17 g tissue per mL PBS) 
and adrenal glands (0.1 g tissue per mL PBS). Tissue homogenates (100 µL) were extracted with cold 
tert-butyl methyl ether (600 µL) containing an internal standard (carfilzomib-d8 250 ng/mL; Cayman 
Chemical, Ann Arbor, MI, USA) by vortex mixing. After centrifugation at 3,724 g for 10 min, 400 µL 
of organic phase was transferred to a new tube, and evaporated. The samples were reconstituted in 100 
µL of ACN and transferred to a new vial for LC-MS/MS analysis. To measure the CFZ concentration 
remaining in plasma, 5 µL of plasma was mixed with H2O (15 µL) and ACN (40 µL) containing an 
internal standard (carfilzomib-d8 250 ng/mL; Cat. No. 22558). After vortex mixing, samples were 
centrifuged at 13,000 g for 10 min. The supernatant (50 µL) was transferred to a new vial for LC-
MS/MS analysis.  
2.6.4. Quantification of CFZ in tissue homogenates  
Samples were analyzed by the HPLC system coupled to Agilent 6460 QQQ LC-MS/MS (Agilent, Palo 
Alto, CA, USA) equipped with an electrospray ionization interface operated in a positive ion mode. 
The chromatographic separation was performed on a C18 column (50 × 2.0 mm id, 3 mm) with a mobile 
phase that consisted of 0.1% formic acid in water (A)-0.1% formic acid in ACN (B) at a flow rate of 
0.3 mL/min. The gradient was set up as follows: 0.5 min 85% A, 15% B; 3 min 100% B; 4 min 100% 
B; 5.5 min 85% A, 15% B; 6 min 85% A, 15% B. The autosampler temperature was set at 4 °C, and 
the injection volume was 10 µL. The optimized source-dependent mass parameters were set as follows: 
nebulizing gas 45 psi; gas flow, 9 L/min; sheath gas flow, 7 L/min; capillary voltage, 4 kV; gas 
temperature, 330 °C. The compound-dependent parameters, fragment voltage and collision energy, 
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were set at 180 V and 60 V for CFZ and carfilzomib-d8 with the dwell time of 50 ms. Quantification 
was performed in the selected reaction monitoring (SRM) mode. The SRM transitions were as follows: 
for CFZ, m/z 720.3 > 100.1 (quantifier) and m/z 720.3 > 289.1 (qualifier); for the internal standard, m/z 
728.3 > 108.1 (quantifier) and m/z 728.3 > 297.1 (qualifier). 
2.6.5. Proteasome activity measurement in tissue homogenates from mice that received drug treatment  
The homogenized tissue samples in PBS (prepared as described in the section 2.6.3.) were mixed with 
the same volume of ice-cold passive lysis buffer (Promega, Madison, WI, USA; Cat. No. E1941). After 
centrifugation of tissue mixtures at 3,000 g for 10 min at 4 °C, the supernatant was collected and used 
for proteasome activity assay (50 – 150 µg total protein/µL verified to be within the linear range of the 
assay using serial diluted samples). For blood samples, the whole blood (0.2 µL) was mixed with ice-
cold passive lysis buffer (1.8 µL), and used for proteasome activity assay. To assess the proteasome 
activity, the tissue supernatant or blood mixture (2 µL) was incubated with 100 µM Suc-LLVY-AMC 
(Bachem, Bubendorf, Switzerland) in the assay buffer (48 µL; 20 mM Tris-Cl buffer (pH 8.0) and 500 
µM EDTA). The proteasome activity was determined by monitoring the initial cleavage rate of 
fluorescent 7-amino-4-methylcoumarine from Suc-LLVY-AMC. Fluorescence signals were detected 
every min for 60 min using a SpectraMax M3 microplate reader (Molecular Devices, CA, USA) at the 
wavelengths of λex/λem = 360/460 nm with the cut-off filter set at 420 nm. 
2.7. Involvement of SPARC in the cellular uptake of CFZ-alb NC 
2.7.1. Quantification of mRNA expression of hSPARC 
Total RNA of breast cancer cells was isolated using PureLink RNA Mini Kit and transcribed to cDNA 
using SuperScript III First-Strand Synthesis kit. The mRNA level of hSPARC was assessed by 
quantitative real-time PCR using TOPrealTM qPCR 2X PreMIX (Enzynomics, Seoul, Korea), the primer 
pair (forward, 5´-tcgacagtcagccgcatct-3´; reverse, 5´-ccgttgactccgaccttca-3´), and StepOnePlusTM Real-
Time PCR system (Applied Biosystems, Foster city, CA, USA). The hGAPDH level was similarly 
measured as a house-keeping control (forward primer, 5´-gggacttcgagaagaac-3´; reverse primer, 5´-
agaggtacccgtcaatg-3´), and the relative hSPARC levels were then calculated using the ∆∆Ct method. 
 42 
2.7.2. Immunoblotting analysis for hSPARC 
Cell lysates were prepared in RIPA buffer, mixed with 4× Laemmli sample buffer, and heated at 95 °C 
for 5 min. Cell lysates containing the equivalent protein amount of 30 µg were resolved using 10% 
SDS-PAGE and transferred onto PVDF membranes (Bio-Rad, Hercules, CA, USA). After blocking 
using 5% milk in Tris-buffered saline containing 0.05% Tween-20 (TBST), the membranes were 
probed with the antibodies for hSPARC (1:200; R&D Systems, Minneapolis, MN, USA; Cat. No. 
AF941) and β-actin (Cell Signaling Technology, Danvers, MA, USA; Cat. No. 4970). After washing 
with TBST, the membranes were incubated with the corresponding secondary antibodies conjugated 
with horseradish peroxidase. Bound antibodies were visualized with an enhanced chemiluminescence 
substrate using ImageQuantTM LAS4000 (GE Healthcare, Little Chalfont, United Kingdom). 
2.7.3. Immunohistochemical analysis for mSparc 
Tissue antigen was retrieved by boiling deparaffinized slides in 10 mM Tris, 1 mM EDTA, and 0.03% 
Tween 20 (pH 9.0) using a pressure cooker. After washing with water and blocking with 4% bovine 
serum albumin in PBS Tween-20 (PBST), slides were incubated with the mSparc antibody (1:20; R&D 
Systems, Minneapolis, MN, USA; Cat. No. AF942) for 60 min at room temperature. After washing 
slides with PBST, a streptavidin-biotin system was used according to the manufacturer's instructions 
(BioGenex, San Ramon, CA, USA). The slides were counterstained with Mayer’s Hematoxylin (Sigma-
Aldrich, St. Louis, MO, USA). All sections were examined under a Vectra imaging system 
(PerkinElmer, Waltham, MA, USA).  
2.7.4. Association between hSPARC expression and overall survival in the TCGA dataset 
To explore a potential association between the hSPARC expression and the outcomes in breast cancer 
patients, the datasets available from the ONCOMINE (www.oncomine.org) were analyzed; the datasets 
were sorted based on the gene name (hSPARC), the analysis type (cancer vs normal analysis), and the 
cancer type (breast cancer). The case dataset containing the hSPARC expression levels and overall 
survival of breast cancer patients was downloaded from a breast cancer meta-data set (reported in 
TCGA, The Cancer Genome Atlas) [31, 32]. 
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2.7.5. Impact of hSPARC knockdown on cellular uptake of CFZ-alb NC in U87MG cells 
To achieve the stable knockdown of hSPARC, U87MG cells were transduced using a lentiviral vector-
based shRNA system targeting hSPARC (obtained from Santa Cruz Biotechnology, Dallas, TX, USA) 
(Detailed experimental methods were reported in the thesis of JH Jo and will soon be published; the 
thesis available at [http://hdl.handle.net/10371/138009]. To assess the cellular uptake of CFZ-alb NC, 
U87MG cells with hSPARC knockdown or wildtype control were seeded on a poly-L-lysine-coated 12-
well plate (at a density of 1×105 cells/well) in complete media containing FBS. After 24 h, cells were 
rinsed with Opti-MEM media, exposed to unformulated CFZ or CFZ-alb NC in Opti-MEM media for 
2 h, and then washed 3 times with PBS. After harvesting cells with 50% methanol (200 µL), aliquots 
of cell lysates were transferred to separate tubes for the measurement of CFZ via LC-MS/MS analysis 
(100 µL) or the protein quantitation assay (30 µL). For LC-MS/MS analysis, cell lysates (100 µL) were 
subject to probe sonication and extracted with ice-cold ACN (100 µL) containing an internal standard 
by vortex mixing. After centrifugation at 3,000 g for 10 min, 150 µL of supernatant was transferred to 
a new vial for LC-MS/MS analysis. 
2.8. Statistical analysis 
All data are presented as mean ± standard deviation (SD) of the replicates from independent 
experiments unless stated otherwise. Student’s t-test or ANOVA with a post-hoc test was performed to 
determine statistical significance using GraphPad Prism (GraphPad Software, version 7.0.3.). A p-value 
< 0.05 was considered significant. 
 
3. Results and discussion 
3.1. Preparation and characterization of CFZ-alb NC  
CFZ-alb NC was prepared following the two-step method as reported previously [28]. In the first step, 
CFZ and F127 (an amphiphilic triblock co-polymer of poly(ethylene oxide)-poly(propylene oxide)-
poly(ethylene oxide)) were dissolved in a mixture of chloroform and methanol and subsequently 
evaporated to form a dry film. Incipient CFZ nanocrystal (CFZ-NC) was formed by hydration of the 
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film. F127 played dual roles: it helped hydrate and retrieve the film from the container (without F127, 
a dry film of CFZ resisted hydration and only 0.02 wt% of CFZ was retrieved from the film) and 
prevented excessive crystal growth of CFZ-NC by binding to the NC surface [17, 33]. In the second 
step, the incipient CFZ-NC was further functionalized with HSA, and the excess HSA and F127 were 
removed by multiple washing.  
The TEM images of CFZ-alb NC showed a rod-like structure with an average length and width 
of 352 ± 195 nm and 58 ± 15 nm, respectively (n=135, analyzed using the Image J software) (Fig. 1A). 
When measured with a dynamic light scattering (DLS), the size and polydispersity index of CFZ-alb 
NC were 270.8 ± 21.5 nm and 0.27 ± 0.06, respectively (n = 10 independently prepared batches) (Fig. 
1B and Table 1). Although the average size of CFZ-alb NC is relatively large compared to other 
nanoformulations, the current size may still be sufficient for extravasation through peritumoral 
vasculature with the reported cut-off size in the range of 200 – 1,200 nm [34-36]. Even if CFZ-alb NC  
 
 
Figure 1. Physicochemical properties of CFZ-alb NC. (A) Representative TEM image of CFZ-alb 
NC and size distribution (analyzed from TEM images, n=135). (B) The average size and zeta 
potential of CFZ-alb NC, measured by DLS. Mean values ± SD (n=10 identically prepared batches). 
(C) The particle size of CFZ NC with or without human serum albumin added during the three 
repeated procedures of centrifugation and washing, measured by DLS. (D) Powder X-ray diffraction 
of CFZ powder (black) and CFZ-alb NC (red). Arbitrary unit (a.u.). (E) Content (%) of CFZ and 
albumin in CFZ-alb NC. Mean values ± SD (n = 6 – 10 independently prepared batches). 
 




















































































































































Table 1. Physicochemical properties of CFZ-alb NC and *CFZ-alb NC. 





Formulation content (wt%) 
CFZ albumin rhodamine B 
CFZ-alb-NC 270.8 ± 21.5 0.27 ± 0.06 -13.7 ± 3.2 74 ± 6 20 ± 4 - 
*CFZ-alb NC 328.0 ± 48.6 0.21 ± 0.09 -8.5 ± 1.1 82 ± 4 16 ± 3 0.34 ± 0.11 
Mean values ± SD from different batches for CFZ-alb NC (n = 10) and *CFZ-alb NC (n = 3). 
 
does not freely traverse the tumor interstitium, CFZ-alb NC may undergo gradual disintegration and 
release CFZ near cancer cells. The shape of NC appears to depend on the drug itself rather than process  
parameters. In the previous reports, docetaxel and paclitaxel form crystals with sheet- and rod-like 
structures, respectively, even with similar procedural methods [27, 28].   The elongated shape of CFZ-
alb NC is also considered advantageous for transvascular flux as compared to the spherical shape at an 
equivalent volume [37, 38] and for resisting uptake by macrophages [39]. CFZ-alb NC was lyophilized 
with trehalose as a cryoprotectant for a long-term storage of the formulation and verified to redisperse 
to the original size (Fig. S1). 
The zeta potential of CFZ-alb NC was -13.7 ± 3.2 mV, likely due to the HSA present on the 
surface of NCs (Fig. 1B and Table 1). The surface-bound HSA protected F127-coated CFZ-NC from 
aggregation (Fig. 1C). In the absence of HSA, CFZ-NC aggregated upon repeated centrifugation and 
washing procedures, as F127 was gradually removed from the NC surface [40]. Under the same 
conditions of multiple centrifugation and washing, the size of CFZ-alb NC did not increase. When 
PXRD patterns were assessed, CFZ powder displayed multiple sharp peaks, indicative of crystalline 
solids, while CFZ-alb NC showed much attenuated peak intensities, indicative of surface-bound HSA 
(Fig. 1D) [28]. The contents of CFZ and albumin in CFZ-alb NC were 74 ± 6 % (w/w) and 20 ± 4 % 
(w/w), respectively (n = 6 independently prepared batches) (Fig. 1E and Table 1). When the weight 
ratio of CFZ to albumin is considered, it is estimated that the albumin content corresponds to 
approximately 1.5 continuous layers of albumin covering the NC surface (Table S1). 
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3.2. Enhanced physical and metabolic stability of CFZ-alb NC  
We next examined whether CFZ-alb NC can display the physical and metabolic stability. In assessing 
the physical stability of NCs in aqueous media, light scattering intensity can serve as a convenient and 
reliable indicator [28, 29]. Stable NCs maintain the light scattering capability, thereby a constant 
derived count rate, whereas disintegrating or dissolving NCs show a decreasing derived count rate. 
When tested in PBS, CFZ-alb NC maintained a linear relationship between the derived count rates the 
concentration within the tested range (7.2 to 72 µg/mL CFZ) up to 24 h (Fig. S2A). In undiluted FBS, 
similar trends were observed with comparable slopes up to 4 h and slightly decreasing slopes at 7 or 24 
h (Fig. 2A). When the derived count rates were continuously monitored over 20 min, CFZ-alb NC (7.2 
µg/mL CFZ, Fig. 2B; 30 µg/mL CFZ, Fig. S2B) yielded the signals consistently greater than those of 
FBS alone. These results support the physical stability of CFZ-alb NC at its concentrations as low as 
 
 
Figure 2. Physical and metabolic stability profiles of CFZ-alb NC. (A) In the presence of undiluted 
FBS, the derived count rates of CFZ-alb NC maintained linear relationships over the concentrations 
ranges tested (7.2 to 72 µg/mL CFZ) for 24 h. (B) The derived count rates of CFZ-alb NC (equivalent 
to 7.2 µg/mL CFZ, in the presence of undiluted FBS) were obtained by continuous monitoring for 
the first 20 min. (C and D) Remaining amount of CFZ following the incubation with CFZ-alb NC, 
cyclodextrin-based CFZ formulation (CFZ-CD), and unformulated CFZ solution in rat liver 
homogenates (C) and whole blood (D). Mean values ± SD (n=3 independently prepared batches of 
CFZ-alb NC). 
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7.2 µg/mL CFZ, even in the presence of serum proteins. When CFZ-alb NC (3 mg/kg, based on the 
CFZ content) is administered to a mouse with a typical blood volume of 1.5 – 2.5 mL [41], the initial 
blood concentration of CFZ-alb NC can be roughly estimated to be 24 – 40 µg/mL CFZ. If the current 
in vitro results measured in undiluted serum were to reflect the physical stability of CFZ-alb NC in vivo, 
one may expect CFZ-alb NC to circulate as intact particulate forms in blood, especially during the early 
hours after drug administration.  
CFZ displays a very short circulation time due to its rapid metabolic inactivation by epoxide 
ring opening and peptide hydrolysis [42]. To assess whether CFZ-alb NC can improve metabolic 
stability, CFZ-alb NC was incubated with rat liver homogenates. As a control, separate reactions were 
performed with CFZ solution (dissolved in DMSO) or clinically used CD-based CFZ formulation 
(CFZ-CD, CFZ dissolved in 10 mM citrate buffer (pH 3.1) containing 20% (w/v) 2-hydroxypropyl-β-
cyclodextrin). At a concentration equivalent to CFZ 1 µM, both CFZ solution and CFZ-CD displayed 
very rapid disappearance of CFZ (<10% remaining after 10 min) in the presence of rat liver 
homogenates (Fig. 2C). These results are consistent with the previous reports showing the half-lives of 
CFZ in various rat tissue homogenates in the ranges of 4 – 39 min [41]. On the other hand, CFZ-alb 
NC displayed much improved stability with approximately 40% of the active drug remaining even at 
60 min in the liver homogenates (Fig. 2C). The disappearance of CFZ after addition of CFZ-alb NC 
and CFZ-CD was quite rapid at early time points and became slower at later time points. The rapid 
disappearance of CFZ at early time points may arise from the readily available portion of CFZ near the 
outer layer of NC formulation. At later time points, the drug release from the disintegration of NC 
formulation may take longer time. Given the results were obtained using liver homogenates (containing 
a variety of metabolizing enzymes and proteins including the proteasome), it is unknown what 
contributes to this biphasic pattern of CFZ disappearance and further investigations are warranted. The 
metabolic stability profiles in whole blood displayed similar trends, finding CFZ-alb NC most stable 
(Fig. 2D). These results indicate that CFZ-alb NC can confer both physical and metabolic stability, 
rendering a promising potential to extend the circulation time of CFZ in vivo.   
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3.3. Enhanced cellular uptake and cytotoxic effects of CFZ-alb NC in breast cancer cell lines 
In order to assess its cellular uptake, CFZ-alb NC was fluorescently labeled using a small quantity of 
rhodamine B. The rhodamine B-labeled CFZ-alb NC (*CFZ-alb NC) was comparable to the unlabeled 
CFZ-alb NC in terms of the average size, zeta potential, and morphology (Table 1 and Figs. S3A and 
S3B), similar to the previous reports with other drugs and nanoformulations [43, 44]. The content of 
incorporated rhodamine B in *CFZ-alb NC was 0.34 ± 0.11 wt% (n = 3). Established breast cancer cell 
lines (murine, 4T1; human, MCF7, HCC1937) were incubated with *CFZ-alb NC (30 µg/mL) for 2 h 
and observed by confocal microscope imaging (Fig. 3A and Fig. S3C). Little signal was obtained from 
the incubation of *CFZ-alb NC in the dish without cells (data not shown), ruling out the possibility that 
the signal obtained with 4T1 cells may come from protein adsorption and subsequent fixation of protein. 
The incubation with *CFZ-alb NC yielded red fluorescence signals localized in the cytoplasm (Fig. 3A, 
d-f), indicating cellular uptake of *CFZ-alb NC (merged images shown in Fig. 3A, f). As a control, free 
rhodamine B solution was tested at an equivalent dye concentration (0.1 µg/mL). As shown in Fig. 3A 
(g-i), the treatment of free rhodamine B showed little signal in all three cell lines (Fig. 3A and S3C). 
No signal from the incubation of *CFZ-alb NC in the dish without cells (data not shown) ruled out the 
plausible signal from protein adsorpition and subsequent fixation of protein. In quantitative analysis by 
flow cytometry, the fluorescent signal intensities were higher in cells treated with *CFZ-alb NC than 
those in the control groups (no treatment or free rhodamine B) for all three cell lines (Fig. 3B). Of the 
*CFZ-alb NC-treated cell lines, HCC1937 cells showed the highest fluorescence signal intensity, 
followed by 4T1 and MCF-7 cells.  
Next, we tested whether the enhanced cellular uptake of CFZ-alb NC leads to greater cytotoxic 
effects in breast cancer cells. When treated with unformulated CFZ, five breast cancer cell line models 
(human: MCF7, MDA-MB-231, HCC1143, and HCC1937; murine: 4T1) displayed IC50 values of low 
nano-molar ranges for CFZ (Fig. S4A). With regard to the expression levels of the proteasome catalytic 
subunits (β1, β2, and β5), the four human breast cancer cell lines tested were comparable to human 
multiple myeloma RPMI8226 cells (well-known for its abundant expression of the proteasome and 
sensitivity to proteasome inhibitor drugs) (Fig. S4B). In addition, the four human breast cancer cells 
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displayed comparable proteasome activities (chymotrypsin-like, trypsin-like, and caspase-like activity, 
typically attributed to β5, β2, and β1 subunits, respectively) to the RPMI8226 cells (Fig. S4C). Although 
the expression and activity of proteasomes were similar across the tested cell lines, MCF7 cells were 
least sensitive to CFZ based on 2D colony formation assay (Fig. S4E). MCF7 cells were also shown to 
be resistant to bortezomib  [5]. The mechanism of MCF7 resistance to proteasome inhibitors remains 
unclear. Since CFZ is a known substrate of P-glycoprotein (P-gp) [44], the P-gp mediated drug efflux 
was initially suspected as a possible resistance mechanism in MCF7 cells, but this was excluded given 
the lack of P-gp expression (Fig. S4D). Cells under 3D spheroid culture conditions are known to enrich 
stem-like cancer cells [45, 46], and the 3D spheroid formation was highest with CFZ-treated MCF7 
cells (Fig. S4F). These results can be cautiously interpreted that a sub-population of stem-like cancer 
cells existing in MCF7 cells may play a role in the resistance to proteasome inhibitors.  
The cytotoxic effects of CFZ-alb NC was tested with either continuous or pulse treatment. 
Upon continuous exposure at low CFZ concentrations (equivalent to 20 and 50 nM for 72 h), CFZ-alb 
NC and unformulated CFZ solution (dissolved in DMSO) displayed similar cytotoxic effects (Fig. 4A). 
 
Figure 3. Cellular uptake of rhodamine B-labeled CFZ-alb NC (*CFZ-alb NC) in breast cancer cell 
lines. (A) Representative confocal microscopy images of HCC1937 cells following 2 h incubation 
with *CFZ-alb NC (30 µg/mL CFZ) (d, e, and f). Free rhodamine B (Rho B) was used as a negative 
control (g, h, and i). Scale bar = 10 µm. (B) Intensities of fluorescent signals associated with breast 
cancer cells (4T1, MCF7, HCC1937) after 2 h incubation with *CFZ-alb NC, measured by flow 
cytometry. Arbitrary unit (a.u.). Two-way ANOVA followed by Tukey’s post hoc test. **p < 0.0021, 
***p < 0.0002. Mean values ± SD (n= 3 independently and identically performed experiments). 
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These results were expected in that CFZ-alb NC would dissolve over time at sufficiently low CFZ 
concentrations. Upon intravenous injection, however, CFZ-alb NC will be present initially at high 
concentrations and rapidly decline, featuring more dynamic changes over time [47, 48]. To mimic such 
conditions, cells were subject to a pulse treatment at high CFZ concentrations (equivalent to 200 or 400 
nM) and grown without CFZ: cells were initially exposed to CFZ-alb NC or CFZ solution for 2 h, rinsed, 
 
Figure 4. Cytotoxic effects of CFZ-alb NC in breast cancer cell lines. Cell viability was measured 
following the treatment of human breast cancer cell lines with CFZ-alb NC or unformulated CFZ 
solution under continuous treatment (Tx) conditions for 72 h (A) or pulse Tx conditions for 2 h 
followed by washout (B). Two-way ANOVA followed by Sidak’s post hoc test. *p < 0.0332, **p < 
0.0021, ****p < 0.0001. Mean values ± SD (n= 4~5 independently and identically performed 
experiments). 
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and grown in drug-free medium for 72 h prior to the measurement of cell viability. Upon a pulse- 
treatment, CFZ-alb NC displayed a greater cytotoxic effect than unformulated CFZ solution (Fig. 4B). 
When the intracellular CFZ content was determined by LC-MS/MS after a pulse treatment in HCC1937 
cells, CFZ-alb NC led to a greater amount of CFZ than unformulated CFZ solution (Fig. S7E; CFZ-alb 
NC vs unformulated CFZ solution; 12.7 vs 7.0 pmol/mg protein). These results collectively suggest that 
CFZ-alb NC gains cellular entry during the initial short exposure to a greater extent than unformulated 
CFZ solution and possibly serves as an intracellular drug reservoir during the incubation in drug-free 
medium. 
3.4. Enhanced in vivo anticancer efficacy of CFZ-alb NC in BALB/c bearing 4T1 breast cancer cells 
The in vivo anticancer efficacy of CFZ-alb NC was assessed using the murine 4T1 orthotopic breast 
cancer model established by the transplantation of 4T1 cells in the mammary fat pad of BALB/c mice , 
which mimic human cancer pathology with tumors growing at the location of human disease in the 
presence of the proper stromal environment compared to the subcutaneous model [49]. Similar to the 
clinical dosing schedule of CFZ [50], intravenous injections of CFZ-alb NC and CFZ-CD (at the 
equivalent CFZ dose of 3 mg/kg) were carried out on two consecutive days per week for three weeks 
(Fig. 5A). CFZ-alb NC or CFZ-CD suppressed tumor growth compared to the vehicle only (Fig. 5B). 
On day 19, the tumor volumes of the mice receiving CFZ-alb NC were smaller than those receiving 
CFZ-CD (p = 0.0024) or the vehicle only (p < 0.0001), while the vehicle- and CFZ-CD-treated groups 
did not show statistical difference. On day 22, all three groups showed difference from each other: CFZ-
CD (p < 0.0001 vs the vehicle only; p < 0.0001 vs CFZ-alb NC) and CFZ-alb NC (p < 0.0001 vs the 
vehicle only; p < 0.0001 vs CFZ-CD). Similar results were obtained for the weight of dissected tumor 
tissues (Figs. 5C and S5A) and specific tumor growth rates (Fig. S5B). During the span of experiment, 
the body weight of mice showed no major difference among the three groups (the overall changes from 
the initial weight was ± 10%, Fig. 5D), suggesting no signs of gross toxicity. The weight loss observed 
near the end of experiment (in all three groups) are likely due to distant metastasis commonly occurring 
in 4T1 tumor models (Fig. S5C). Histological examination of major organs (liver and lung) also showed 
no signs of major toxicities in three groups (Fig. S5D).  
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At the end of the in vivo anticancer efficacy experiments described above, we collected the 
tumor tissues and blood samples on day 22 (3 days following the last drug dosing on day 19) and 
attempted to quantify the CFZ levels by LC-MS/MS. The levels of CFZ in tumor tissues were below 
the lower limit of quantitation (< 1 ng/mL), but those of CFZ in plasma samples were higher in mice 
receiving CFZ-alb NC than CFZ-CD (Fig. 5E). Because CFZ is a covalent modifier, which forms an 
 
Figure 5.  In vivo anticancer efficacy of CFZ-alb NC in BALB/c mice bearing 4T1 orthotopic 
xenograft tumors. (A) Experiment schedule including drug treatments. Mice received intravenous 
injections of CFZ-alb NC (n = 5; 3 mg/kg), CFZ-CD (n = 5; 3 mg/kg), or vehicle control (n = 6) on 
two consecutive days per week for three weeks. (B) Tumor growth curves. Two-way ANOVA 
followed by Tukey’s post hoc test. On day 19: CFZ-alb NC vs vehicle, *p < 0.0001; CFZ-alb NC vs 
CFZ-CD, †p = 0.0024. On day 22: CFZ-alb NC vs vehicle, *p < 0.0001; CFZ-CD vs vehicle, §p < 
0.0001; CFZ-alb NC vs CFZ-CD, ††p < 0.0001 (C) The weight of tumor tissues harvested on day 
22. One-way ANOVA followed by Tukey’s post hoc test. **p < 0.0021, ****p < 0.0001. (D) The 
body weight of mice during the span of experiment. (E) The concentration of CFZ from plasma 
collected on day 22 (n.d.; not detected). Mean values ± SD. 
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irreversible CFZ-proteasome complex undetectable by LC-MS/MS [51, 52], the drug amount measured 
by LC-MS/MS may not accurately represent the total amount of CFZ reaching a particular tissue (as 
depicted in Fig. 6B). The recovery of the proteasome activity following inhibition is known to take at 
least several days due to the slow de novo biogenesis rates of proteasomes [53]. Thus, we examined the 
inhibitory extent of the proteasomal activity in tissues as another indicator of the CFZ distribution. In 
whole blood samples, the inhibitory extent of the proteasome activity was greater in the CFZ-alb NC 
group than in the CFZ-CD group (p < 0.0001) (Fig. S5B), consistent with the blood levels of CFZ (Fig. 
5E). These results suggest that CFZ-alb NC increased the formation of the irreversible, long-lasting 
complex between CFZ and the proteasome in whole blood (mainly located in red blood cells), likely 
from the enhanced stability and cellular uptake of CFZ-alb NC over CFZ-CD. 
3.5. Comparison of PK and BD profiles of CFZ-alb NC with CFZ-CD 
In the previous study, albumin-coated paclitaxel NC was superior in anticancer efficacy and showed 
more favorable plasma PK and BD profiles compared to Abraxane® at the equivalent paclitaxel dose 
level [21]. To examine whether CFZ-alb NC confers similar advantages, we first examined the plasma 
PK profiles of CFZ-alb NC relative to those of CFZ-CD (an equivalent CFZ dose of 3 mg/kg) in ICR 
mice. Following a single intravenous administration, the plasma CFZ concentrations declined very 
rapidly in both groups (Fig. 6A). The PK parameters obtained via non-compartmental analysis did not 
show major differences between the two groups (Table 2). The volume of distribution at steady-state 
(Vss, 19.85 ± 0.04 L/kg and 17.01 ± 9.40 L/kg for CFZ-alb NC and CFZ-CD, respectively) and the 
plasma half-lives (t1/2, terminal, 387 ± 49 min and 796 ± 393 min; t1/2, initial, 21 ± 4 min and 19 ± 5 min for 
CFZ-alb NC and CFZ-CD, respectively). The Vss and t1/2, initial values of CFZ-CD were comparable to 
the previously reported values [11, 41, 48]. The t1/2, terminal values tended to be longer with CFZ-alb NC 
than with CFZ-CD, but the differences did not reach statistical significance due to large variability. The 
systemic exposure of CFZ (assessed by AUCinf) was slightly greater with CFZ-alb NC (57.5 ± 14.0 
min×nmol/mL) than with CFZ-CD (45.4 ± 6.9 min×nmol/mL), although the difference did not reach 
statistical significance. Likewise, the systemic clearance was slightly slower with CFZ-alb NC than 
with CFZ-CD but did not show statistical significance (76 ± 21 mL/min/kg and 94 ± 15 mL/min/kg for 
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CFZ-alb NC and CFZ-CD, respectively). Similar to the previous reports [11, 41], the clearance of both 
CFZ-alb NC and CFZ-CD was considerable fast, almost approximating to the hepatic blood flow in 
mice [54]. These results suggest that the extrahepatic metabolism likely plays an important role in the 
elimination of CFZ in both groups. Overall, CFZ-alb NC appeared to have a modest improvement over 
CFZ-CD with regard to the plasma PK profiles. 
Table 2. Pharmacokinetic (PK) parameters following the intravenous administration of CFZ-alb NC or 
CFZ-CD at an equivalent CFZ dose of 3 mg/kg to ICR mice. 
PK parameter (unit) CFZ-alb NC (n = 3) CFZ-CD (n = 4) 
AUCinf (min×nmol/mL) 57.5 ± 14.0 45.4 ± 6.9 
CL (mL/min/kg) 76 ± 21 94 ± 15 
Vss (L/kg) 19.85 ± 0.04 17.01 ± 9.40 
t1/2, terminal (min) 387 ± 49 796 ± 393 
t1/2, initial (min) 21 ± 4 19 ± 5 
MRT (min) 192 ± 125 274 ± 67 
AUCinf, area under the concentration-time curve from time 0 to infinity; Vss, volume of distribution at steady state; 
t1/2, terminal, half-life from the terminal phase; t1/2, initial, half-life from the initial decline phase (0 – 120 min); MRT, 
mean residence time; CL, clearance. Student’s t-test indicated no significant difference. Mean values ± SD.  
 To examine whether CFZ-alb NC can enhance tumor distribution of CFZ, BALB/c mice 
bearing 4T1 tumors were injected with a single intravenous dose of CFZ-alb NC or CFZ-CD (an 
equivalent CFZ dose of 3 mg/kg). Tumor tissues and major organs were harvested at 0.5, 2, or 6 h post-
injection, processed to make tissue homogenates, and subsequently analyzed with respect to the CFZ 
levels by LC-MS/MS (the remaining CFZ quantity as either NC or released CFZ) and the proteasome 
activity by the enzyme kinetics assay (likely representing the cumulative CFZ access to a given tissue 
and the formation of the CFZ-proteasome complex in a given tissue). In tumor tissues, the CFZ-alb NC 
group displayed significantly higher CFZ levels than the CFZ-CD group at 0.5 h post-dosing (9.2 ± 1.7 
vs 6.8 ± 1.1 nM CFZ/g tissue, p = 0.028) (Fig. 6C). However, this trend was reversed at 2 and 6 h post-
dosing, where CFZ-alb NC group displayed lower CFZ levels than the CFZ-CD group (at 2 h, 4.3 ± 0.4 
vs 8.2 ± 2.2 nM CFZ/g tissue, p = 0.0003; at 6 h, 1.4 ± 0.5 vs 7.0 ± 1.2 nM CFZ/g tissue, p < 0.0001). 
When we compared the extent of proteasomal activity inhibition (by forming the irreversible CFZ-




Figure 6.  Comparison of pharmacokinetic and biodistribution profiles between CFZ-alb NC and 
CFZ-CD following the intravenous administration (a single equivalent CFZ dose of 3 mg/kg). (A) 
The plasma concentration-time profiles of CFZ after the administration of CFZ-alb NC (n = 3) or 
CFZ-CD (n = 4) in ICR mice. Inset, plasma concentration-time profiles of CFZ for the first 2 h. 
(B) Diagram depicting the irreversible biding of CFZ with the proteasome in tissues. The resulting 
CFZ-proteasome complex is not measurable by LC-MS/MS, but can be indirectly assessed by 
measuring the inhibitory extent of the proteasomal activity. (C, D, and E) The results showing the 
measured amount of CFZ and the inhibitory extent of the proteasome activity in tumor tissues and 
major organs in BALB/c mice harboring 4T1 xenograft at 0.5, 2, and 6 h following the 
administration of CFZ-alb NC or CFZ-CD (n = 4 – 5 per group). The measured amount of CFZ 
(C) and the inhibitory extent of the proteasomal activity (D) in tumor tissues. (E) The measured 
amount of CFZ in major organs. Two-way ANOVA followed by Sidak’s post hoc test. *p < 0.0332, 
***p < 0.0002, ****p < 0.0001. Mean values ± SD. 
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of the proteasomal inhibition than the CFZ-CD group (2 h post-dosing, 27% ± 5% for CFZ-CD vs 45% 
± 9% for CFZ-alb NC, p = 0.0112) (Fig. 6D). The CFZ levels and proteasome activity in tumors, taken 
together, suggest that CFZ-alb NC was rapidly entrapped into tumor tissues after administration, 
subsequently releasing CFZ, and forming the CFZ-proteasome complex.  
In both CFZ-alb NC and CFZ-CD groups, CFZ was predominantly distributed to the liver, the 
lung, and the spleen at 0.5 h post-dosing with a minor distribution into the kidney, the heart, adrenal 
glands, and the brain (Figs. 6E and S6A). CFZ-alb NC recognized and sequestered by mononuclear 
phagocytic system (MPS) as exogenous materials likely to be accumulated in MPS-rich organs, such 
as the liver, the lung, and the spleen [18]. Similar to the plasma PK profiles, CFZ levels in various 
tissues rapidly declined within 6 h post-injection. At 2 and 6 h post-injection, the CFZ-CD group 
resulted in CFZ levels in the liver, lung, and spleen comparable to or even higher than CFZ-alb NC 
group (Figs. 6E and S6A). In the liver (at 2 and 6 h post-dosing), the CFZ-alb NC group showed more 
pronounced inhibition of the proteasome activity than the CFZ-CD group (Fig. S6B). CFZ-alb NC 
group had lower CFZ levels than CFZ-CD group in the liver, reminiscent of the results obtained in 
tumor tissues (Figs. 6C and 6D). No apparent organ toxicity of CFZ-alb NC was observed based on 
histological examinations (Fig. S5D). For CFZ-alb NC, the initial accumulation in the RES organs and 
very limited distribution to the brain were observed as expected from typical nanoparticle interactions 
and uptake by liver sinusoidal endothelial cells and Kupffer cells, mechanical filtration [55, 56], and 
poor penetration through the blood brain barrier [57].  
The results in CFZ-CD group were rather surprising. Currently, the quantitative data of CFZ 
BD profiles by LC-MS/MS is limited. An early study used whole-body autoradiogram in rats after an 
intravenous injection of [3H]-CFZ (a total CFZ dose of 2 mg/kg, prepared as an injectable CFZ-CD 
solution) and found predominant distribution of the radioactivity in the liver and lung [58]. It is 
unknown whether these observed profiles are attributable to the intrinsic properties of CFZ or CD itself. 
CD derivatives are generally assumed to have a minimal impact on the PK profiles of drugs [59]. 
However, there are cases where the complexation with CD alters the systemic exposure of certain 
compounds, especially those with high affinity for CD derivatives [60]. It remains to be determined 
whether the complexation with CD enhanced the distribution of CFZ to the liver and lung.  
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3.6. SPARC-dependent uptake of CFZ-alb NC to cancer cells  
In line with the proposed role of SPARC present in the tumor microenvironment facilitating tumor 
accumulation of nab-drugs [23, 61], a positive association was reported between SPARC expression 
and response to nab-paclitaxel in multiple types of cancers (e.g., human head-and-neck cancer, non-
small cell lung cancer, HER2-positive breast cancer) [62-64]. However, SPARC-independent pathways 
may also play a role in delivering nab-drugs to cancer cells [65, 66]. The relative importance of SPARC 
and non-SPARC pathways may well vary depending on cellular context and cancer types. In the case 
of breast cancer, the results from publicly available databases indicated that the hSPARC expression 
was higher in breast cancer tissues than in non-malignant control tissues (Fig. 7A). From the dataset 
collected from 498 breast cancer patients, the sub-groups with high and low hSPARC levels (top 10% 
and bottom 10% in the SPARC expression levels, respectively; n = 50 each) were identified and 
compared for their median survival. The higher hSPARC expression level was associated with poorer 
outcomes (median survival times of 23 and 31 months in the high and low hSPARC expression groups, 
respectively) (Fig. 7B; Fig. S7A showed similar trend in another dataset (n = 418)).  
To investigate the potential involvement of SPARC in the delivery of CFZ-alb NC to cancer 
cells, we first compared the SPARC level among four human breast cancer cell lines used in our study. 
HCC1937 cells were highest in the mRNA and protein level of hSPARC, followed by HCC1143, MDA-
MB-231, and MCF7 cells (Figs. 7C and 7D). hSPARC showed an apparent positive correlation with 
cellular uptake of CFZ-alb NC (HCC1937 taking up a greater amount of CFZ-alb NC than MCF7) (Fig. 
3B) and also with cytotoxicity of CFZ-alb NC (HCC1937 displaying the greatest enhancement of 
cytotoxicity by CFZ-alb NC over the unformulated CFZ solution, followed by HCC1143, MDA-MB-
231, and MCF7) (Figs. 4B and S7B). hSPARC expression was detected mainly on the plasma 
membrane of HCC1937 cells (Fig. S7C), and mSparc was abundantly expressed in the 4T1 tumor tissue 
sections (Fig. 7E). Based on these results, it was postulated that the SPARC expressed in or near cancer 
cells may facilitate cellular interactions and internalization of CFZ-alb NC, potentially accounting for 






Figure 7. Role of SPARC in the uptake of CFZ-alb NC into cancer cells. (A) The relative expression 
of hSPARC gene in normal vs cancerous breast tissues (from a dataset in the TCGA database, n = 
64; the detailed description provided in the methods). (B) The Kaplan-Meier curves depicting 
overall survival for breast cancer patients with a high and low levels of hSPARC (n = 498, the 
dataset from the previous report [31]). (C and D) The mRNA (C) and protein (D) expression level 
of hSPARC in breast cancer cell lines. (E) Immunohistochemical staining of mSPARC (positive 
staining visualized as brown colors using 3,3'-diaminobenzidine) in 4T1 tumor tissue sections. 
Normal lung tissue section showed a weak staining signal for mSparc under the same experimental 
condition (representative images, scale bar = 100 µm).  (F) The protein levels of hSPARC in 
HCC1937 and U87MG cells following the lentiviral transduction of SPARC-targeting shRNA. (G 
and H) Comparison of the cellular uptake of CFZ (G) and cell viability (H) in U87MG cells where 
SPARC was completely knocked down following exposure to CFZ-alb NC or unformulated CFZ 
solution. Two-way ANOVA followed by Tukey’s post hoc test. ***p < 0.0002, ****p < 0.0001. 
Mean values ± SD. 
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To obtain experimental evidence on the involvement of SPARC in the cellular uptake of CFZ-
alb NC, we examined changes in cellular uptake and cytotoxicity of CFZ-alb NC in breast cancer cells 
by modulating their SPARC levels. When SPARC was partially knocked down by transient siRNA 
transfection in HCC1937 cells (Fig. S7D), no appreciable change was observed in cellular uptake (Fig. 
S7E) or cytotoxicity (Fig. S7F) of CFZ-alb NC. Boosting SPARC levels using decitabine (Fig. S7G) 
[63] also did not change the cellular uptake (Fig. S7H) and cytotoxic effects (Fig. S7I) of CFZ-alb NC. 
In order to obtain more conclusive evidence on the involvement of SPARC in the cellular uptake of 
CFZ-alb NC, we employed a model system that allows for a complete knockdown of SPARC from its 
high basal expression level. High levels of endogenous SPARC have been reported in glioma [67, 68], 
especially in U87MG cell lines derived from human glioblastoma. Upon lentiviral transduction of 
SPARC-targeting shRNA, U87MG cells showed an almost complete knockdown of SPARC at the 
protein level (Fig. 7F), making it suitable for the proof-of-concept study. When the cellular uptake and 
cytotoxicity of CFZ-alb NC were assessed in U87MG cells with complete SPARC knockdown, CFZ-
alb NC displayed dramatic increases in both the cellular uptake (Fig. 7G) and cytotoxicity (Fig. 7H) 
compared to the control U87MG cells. These results provide clear evidence supporting the important 
role of SPARC in delivering albumin-containing nanoparticles to cancer cells and may warrant further 
exploration of albumin coating for the therapy of SPARC-overexpressing tumors including gliomas.  
Taken together, our results support that CFZ-alb NC enhances pharmacodynamics of CFZ 
compared to CFZ-CD formulations by improving its physical and metabolic stability and enhancing 
cellular uptake by cancer cells. The extent by which CFZ-alb NC improved the anticancer efficacy 
compared to CFZ-CD was not as pronounced as albumin-coated paclitaxel NC (reported as Cim-F-alb 
[21, 28]). Possible reasons include the followings: (a) The size of CFZ-alb NC was larger than Cim-F-
alb (270 vs 198 nm). It was previously shown that the cellular uptake of paclitaxel NCs significantly 
decreased as the particle size increased [28]. (b) The conformational status of surface-bound albumin 
was shown to be an important factor to determine the efficacy of NCs [21]. When the extent of 
proteolysis by thermolysin was compared using the pulse proteolysis method [28], the surface-bound 
albumin in CFZ-alb NC was comparable to native albumin (23.9 ± 3.9% vs 15.8 ± 5.1%, n=3), whereas 
denatured albumin (boiled at 95 °C for 10 min as a positive control) showed significantly higher extent 
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of proteolysis than native albumin (42.0 ± 9.5% vs 15.8 ± 5.1%, n=3). Given the slightly elevated 
proteolysis, the possible impact of albumin conformation changes on the performance of CFZ-alb NC 
may not be completely ruled out, but the majority of albumin in CFZ-alb NC appears to maintain its 
native conformation.  (c) Different levels of albumin-interacting proteins including SPARC may impact 
the extent by which the surface-bound albumin facilitates cellular uptake. Cim-F-alb was tested in 
C57BL/6 mice harboring xenografts of B16F10 melanoma cells [21], which showed much greater 
SPARC expression level than 4T1 cells used in our current study [69]. (d) The improvement in the 
circulation time might have been less with CFZ-alb NC than albumin-coated paclitaxel nanocrystal. 
Given that paclitaxel has aqueous solubility even lower than CFZ, albumin-coated paclitaxel 
nanocrystal may have had a longer circulation time as NCs than CFZ-alb NC. Moreover, albumin-
coated paclitaxel nanocrystal was administered at 30 mg/kg, much higher than 3 mg/kg for CFZ-alb-
NC. Consideration of these possibilities may assist in optimizing CFZ formulations containing albumin 
for the treatment of breast cancer and other types of solid cancer. Nonetheless, our results indicate a 
promising potential for CFZ-alb NC as an alternative, CD-free formulation which can improve in vivo 
anticancer efficacy.   
 
4. Supporting information 
4.1. Supporting experimental methods 
4.1.1. Cytotoxic effects of CFZ solution  
Breast cancer cells were seeded onto 96-well plates 24 h prior to drug treatment. Cells were treated with 
CFZ solution (dissolved in DMSO; CFZ concentrations ranging from 1 to 500 nM; the DMSO content 
did not exceed 0.5% v/v) for 72 h and the cell viability was measured with the CellTiter 96® AQueous One 
Solution Cell Proliferation Assay (Promega, Madison, WI, USA) using Synergy HT plate reader 
(BioTek, Winooski, VT, USA). The IC50 (half maximal inhibitory concentration) value was obtained 
using GraphPad Prism software 7.0.3. 
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4.1.2. Immunoblotting analysis  
Cell lysates were prepared in the RIPA buffer, mixed with 4× Laemmli sample buffer, and heated at 95 
°C (for the proteasome subunits) or 50 °C (for P-glycoprotein, P-gp) for 5 min. Cell lysates containing 
the equivalent protein amount (10 µg for proteasome subunits, 60 µg for P-gp) were resolved using 7.5 
– 12% SDS-PAGE and transferred onto PVDF membranes (Bio-Rad, Hercules, CA, USA). After 
blocking using 5% milk in Tris-buffered saline containing 0.05% Tween-20 (TBST), the membranes 
were probed with the following antibodies: β1 (1:1,000 dilution; #PW8140; Enzo Biochem, 
Farmingdale, NY, USA), β2 (1:1,000 dilution; #PW8145; Enzo Biochem, Farmingdale, NY, USA), β5 
(1:1,000 dilution; #PA1-1962; Thermo Fisher Scientific) and P-gp (1:200 dilution; #903701; 
BioLegend, San Diego, CA, USA).  
4.1.3. Proteasome activity measurement in breast cancer cell lines  
Cell lysates were prepared in the ice-cold passive lysis buffer (Promega, Madison, WI, USA). After 
centrifugation of cell lysates at 3,000 g for 10 min at 4 °C, the resulting supernatant was collected and 
used for the proteasome activity assay (10 µg total protein). To assess the proteasome activities, the 
supernatant (2 µL) was incubated in the assay buffer (48 µL) with the following fluorogenic substrates: 
100 µM Suc-LLVY-AMC (Bachem, Bubendorf, Switzerland) for the chymotrypsin-like activity, 100 
µM Ac-nLPnLD-AMC (Bachem, Bubendorf, Switzerland) for the caspase-like activity, and 20 µM Ac-
RLR-AMC (BostonBiochem, Cambridge, MA, USA) for the trypsin-like activity. The proteasome 
activities were monitored as described in section 2.6.5.  
4.1.4. 2-dimensional (2D) colony formation assay  
Breast cancer cells were seeded onto a 6-well plate at a density 1,000 – 2,000 cells per well. After 
treated with CFZ solution for 2 h and subsequently washed twice with DPBS, cells were maintained in 
drug-free complete media for 11 – 14 days. After the removal of media, cell plates were placed on ice, 
washed twice with ice-cold DPBS and fixed with cold methanol for 10 min. The fixed cells were 
strained with crystal violet solution.  
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4.1.5. 3-dimenstional (3D) spheroid formation assay 
Cells were seeded onto a 6-well plate at a density 5×104 cells per well in complete media. Cell were 
treated with CFZ (50 nM) and doxorubicin (100 nM) for 16 h, and then washed twice with DPBS.  Cells 
were collected using trypsin and 500 – 2,000 cells were re-plated per well in ultra-low attachment 96 
well plates (Corning, New York, USA). Cells were maintained in HuMEC Ready Medium 
supplemented with B-27 Supplement, epidermal growth factor (20 ng/mL; Sigma-Aldrich, St. Louis, 
MO, USA), basal fibroblast growth factor (20 ng/mL), heparin (4 µg/mL; Sigma-Aldrich, St. Louis, 
MO, USA), and penicillin-streptomycin at 37 °C in a humidified incubator operating at 5% CO2. After 
10 – 14 days, spheroids were visualized using Operetta imaging system (PerkinElmer, Waltham, MA, 
USA) and the number of spheroids with their size > 500 nm was counted.    
4.1.6. hSPARC imaging in HCC1937 cells  
HCC1937 cells were seeded in 35 mm petri dish at 1×105 cells per dish and incubated overnight. The 
cells were fixed in 4% paraformaldehyde at 4 ˚C for 15 min, rinsed twice with PBS, and incubated with 
10 µg/mL of polyclonal goat anti-human SPARC antibody (R&D Systems, Minneapolis, MN, USA) 
overnight at 4 ˚C in 5% milk in TBST. After washing, the primary antibody was visualized with Alexa 
Fluor 488 conjugated-polyclonal rabbit anti-goat IgG (10 µg/mL; Invitrogen, Carlsbad, CA, USA) by 
incubating for 1 h at 4 ̊ C. The stained cells were imaged with a Nikon A1R confocal microscope (Nikon 
America Inc., Melville, NY, USA), and Hoechst 33342 and Alexa Fluor 488 were detected with λex/λem 
of 407 nm/425 – 475 nm and λex/λem of 488 nm/500 – 550 nm, respectively. 
4.1.7. siRNA-based hSPARC knockdown in HCC1937 cells 
HCC1937 cells at the confluency of approximately 60% were transfected with hSPARC-targeting 
siRNAs (25 picomole; OriGene, Rockville, MD, USA) or scrambled siRNAs using Lipofectamine® 
RNAiMAX Reagent following the recommended protocol. At 48 h post-transfection, cells were 
harvested for the immunoblotting analysis of SPARC protein. To assess the cytotoxicity and cellular 
uptake of CFZ-alb NC, the transfected HCC1937 cells were treated with CFZ-alb NC or CFZ solution 
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for 2 h. After washing 2 – 3 times with PBS, cells were either grown for 72 h in drug-free media 
(cytotoxicity) or harvested with 50% methanol (uptake assay).  
4.1.8. SPARC upregulation in HCC1143 cells 
HCC1143 cells (confluency of approximately 50%) were pre-treated with decitabine solution in DMSO 
(5 µM; Shenzhen Chemical Co. Ltd., Shanghai, China) or DMSO (as a control) for three consecutive 
days. After 24 h, cells were either harvested for verifying the upregulation of hSPARC (by 
immunoblotting analysis) or re-plated on 96-well-plates. After 24 h, the HCC1143 cells were treated 
with CFZ-alb NC or CFZ solution for 2 h. After washing 2 – 3 times with PBS, cells grown for 72 h in 
drug-free media were accessed cytotoxicity. 
4.2. Supporting table 
Table S1. Theoretical calculation of the amount of human serum albumin (HSA) needed for coating 
CFZ NCs. 
Surface area of occupying HSA molecule [1] 39 nm2 
Total surface area of each NC particle (352 nm × 58 nm) × 4 + (58 nm × 58 nm) × 2  
= 8.84 × 104 nm2 
Theoretical maximum number of HSA on each NC 
particle 
approximately 2,267 
Volume of each NC particle 352 nm × 58 nm × 58 nm = 1.18 ×106 nm3 
Density of CFZ 1.2 g/cm3 
  
For CFZ-alb NC  
74% CFZ (74 g/1.2 g cm-3) × (1021 nm3 cm-3) / (1.18 x 106 nm3) 
= 5.23x1016 NC 
20% HSA (20 g/66,437 g mol-3) × (6.022 x 1023 molecules/mol) 
= 1.81x1020 HSA molecules 
 










Figure S1. (related to Figure 1) The particle size of CFZ-alb NC reconstituted after 
lyophilization, measured by DLS. Trehalose was added at varying weight ratios prior to 
lyophilization. 
 
Figure S2. (related to Figure 2). (A) The derived count rates of CFZ-alb NC in PBS maintained 
linear relationships over the concentrations ranges tested (7.2 to 72 µg/mL CFZ) for 24 h. (B) 
The derived count rates of CFZ-alb NC (equivalent to 30 µg/mL CFZ, in the presence of 






Figure S3. (related to Figure 3). (A) Representative TEM image of rhodamine B-labeled CFZ-
alb NC (*CFZ-alb NC) (B) The average size and zeta potential of *CFZ-alb NC, measured by 
DLS. (C)   Cellular uptake of *CFZ-alb NC in breast cancer cell lines (4T1 and MCF7). 
Representative confocal microscopy images following 2 h incubation with *CFZ-alb NC (30 





Figure S4. (related to Figure 4) The sensitivity of breast cancer cell lines to CFZ. (A) The cytotoxic 
effects of CFZ in breast cancer cell lines following continues treatment for 72 h. (IC50, half maximal 
inhibitory concentration; n.d., not determined) (B and C) The expression of proteasome catalytic 
subunits (β1, β2, and β5) and proteasomal activities in breast cancer cell lines. Human multiple 
myeloma RPMI8226 cells were used as a positive control. (D) The expression level of P-
glycoprotein (P-gp) in breast cancer cell lines. NCI-ADR/RES cells were used as a positive control. 
(E and F) The inhibitory effect of CFZ on 2D-colony (E) and 3D spheroid (F) formation in breast 
cancer cell lines after 2 h and 16 h incubation, respectively, followed by the maintenance in drug-
free media for 11 – 14 days. Representative images of the spheroids formed in HCC1143 cells. Mean 






Figure S5. (related to Figure 5) (A) Representative images of tumor harvested on day 22. (3 days 
following the last injection) (B) The proteasome activity from whole blood collected on day 22. 
One-way ANOVA followed by Tukey’s post hoc test. ****p < 0.0001 (a.u.; arbitrary units). (C) 
Representative images of lung harvested on days 24 and 28 after inoculation of 4T1 cells in 
BALB/c mice. ▲ indicated metastasis lung nodules. (D) Histological examination of liver and 







Figure S6. (related to Figure 6) (A) The amount of CFZ per gram tissue in the major organs. (B) 
The amount of CFZ (left y-axis, shown as a bar graph) and the inhibitory extent of the proteasomal 





Figure S7. (related to Figure 7). (A) Kaplan-Meier curves depicting the overall survival of breast 
cancer patients with the low and high expression levels of hSPARC (n = 418, extracted from [3]). 
(B) Correlation between the mRNA expression level of hSPARC and the extent of enhanced 
cytotoxicity of CFZ-alb NC relative to unformulated CFZ solution at the concentration of 400 nM. 
(C) SPARC expression on the plasma membrane in HCC1937 cells. Green: anti-human SPARC 
antibody. Blue: nuclei stained with Hoechst 33342. (D) hSPARC expression in HCC1937 cells 
transfected with scrambled (sc) siRNA (negative control) or two different siRNAs targeting 
hSPARC. (E & F) The amount of CFZ (E) and cell viability (F) in HCC1937 cells transfected with 
hSPARC-targeting siRNA following the exposure to CFZ-alb NC or CFZ solution. Two-way 
ANOVA followed by Tukey’s post hoc test (H) or Sidak’s post hoc test (I). (G) hSPARC 
expression in HCC1143 cells pre-treated with decitabine. (H & I) The amount of CFZ (H) and cell 
viability (I) in HCC1143 cells which showed a modest upregulation of SPARC following the 





With the clinical successes of three FDA-approved proteasome inhibitor (PI) drugs (bortezomib, BTZ; 
carfilzomib, CFZ; ixazomib, IXZ), the PI therapy is firmly established as a mainstay for the treatment 
of multiple myeloma (MM) and other hematological malignancies. Yet, there remains much room for 
further improvement, especially with regards to drug resistance (intrinsic and acquired), poor efficacy 
against solid cancers and adverse effects (via on-target and off-target interactions). For CFZ, its 
pharmacokinetic aspects (namely, rapid metabolic inactivation and short circulation time) have also 
been suspected as a factor limiting its efficacy against solid cancer. To improve upon existing PI drugs, 
a number of next-generation PIs are currently under clinical and preclinical development. With data 
accumulating from new PI drug candidates, it has become increasingly evident that the clinical efficacy 
of PI drugs is impacted not only by their inhibitory potency, but also by the mode, extent and duration 
of proteasome inhibition. Moving forward, a careful examination of the pharmacokinetic (PK) and 
pharmacodynamic (PD) profiles of PI drug candidates may provide important insights in bridging the 
current gap between initial preclinical results and eventual clinical outcomes.  
 Many of the oncology-based nanoformulations are designed to enhance the drug delivery to 
tumor tissues, thus broadening the therapeutic window. In this thesis work, both of novel CFZ 
nanoformulations (polymer micelle-based formulation, CFZ-PM (Chapter I); nanocrystal with albumin 
coating, CFZ-alb NC (Chapter II)) improved metabolic stability in vitro. In the case of CFZ-PM, the 
improvement observed in vitro however did not yield a similar improvement in vivo (in terms of plasma 
PK profiles and anticancer efficacy in a mouse model carrying lung cancer xenografts). The lack of 
translatability from in vitro to in vivo may be attributed to multiple factors, but it would be important 
to keep in mind that in vitro results may not predict the in vivo performances of nanomedicine-based 
chemotherapeutics (especially, the stability in circulation and drug distribution at the tissue/cellular 
levels).  
So far, the accumulating body of information suggests that novel approaches including 
previously unexplored structural scaffolds may address limitations of PIs and further expand the utility 
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of existing PI drugs harboring peptide scaffold. As an approach to improve bio- and/or physico-
chemical properties of peptide-based drugs, macrocyclization (yielding so-called constrained peptides) 
can be applied to CFZ or next-generation PI drug candidates. Macrocyclization of peptide-based 
compounds may improve the plasma stability of peptide- or peptidomimetic-based small molecules 
compared to linear peptides [155][DR Cary et al., J-STAGE, 2017]. In an attempt to develop orally 
available and metabolically stable PIs, a recent report synthesized the structurally diverse PI-
derived macrocyclic peptides containing epoxyketone pharmacophore and the compounds displayed 
superior in vivo metabolic stability with potent proteasome inhibition [156].  Additionally, alternative 
targets in the ubiquitin-proteasome system (other than the catalytic subunits of the proteasome) present 
promising therapeutic potential and preclinical evaluation of compounds targeting such targets is 
underway. In particular, deubiquitinases (DUBs), an essential component in the UPS, have emerged as 
a novel target in cancer therapy, especially for cancers refractory to existing PI drugs. These efforts 
may yield therapeutic agents targeting non-proteasomal components of the UPS, used on their own or 
in combination with PI drugs.  
In this thesis work, our efforts of developing CFZ nanoformulations (i.e., polymer micelles and 
nanocrystals coated with albumin) did not achieve the marked efficacy against lung and breast cancer 
falling short of our initial expectations. However, other drug delivery systems may still offer further 
improvements of the pharmacokinetics, biodistribution and pharmacodynamics of CFZ. In exploring 
other drug delivery systems, it would be important to consider the exposure and release profiles (the 
extent and kinetics) of the drug in circulation and in tumor tissues. With continuing efforts, it is hoped 
that next-generation PIs with improved pharmacokinetic and pharmacodynamic profiles will eventually 
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요약 (국문 초록) 
 
현재 임상에서 사용되고 있는 2 세대 프로테아좀 저해제인 carfilzomib (CFZ)은 1 세대 
프로테아좀 저해제인 bortezomib 과 더불어 다발성 골수종 치료에 매우 획기적인 치료효과를 
나타내고 있다. CFZ 은 bortezomib 보다 향상된 항암 효과 뿐만 아니라, 
구조적으로 epoxyketone pharmacophore 를 가지고 있어 타겟인 프로테아좀에 보다 
선택적으로 반응하여 개선된  안전성 프로파일을 나타낸다. 하지만 수용성이 매우 낮고 1 시간 
이내에 체내에서 대부분 소실되는 경향을 보인다는 제한점이 있다. 이는 CFZ 의 펩타이드 
backbone 과 epoxyketone  구조가 대사 반응에 취약하여, 체내 대사가 빠른 시간 내에 
일어나기 때문에 짧은 반감기의 약물동태학적 특성을 보이는 것으로 사료된다. 이러한 제한 
점을 극복하기 위해 나노제형을 도입한다면 CFZ 의 약물동태학적 문제점을 해결하고 더 
나아가 약물동력학적 특성도 개선할 수 있어 고형암 환자에게 적용 가능성의 향상을 또한 
예상하는 바, 본 연구에서는 CFZ 의 새로운 나노제형을 개발하고 고형암 세포주와 실험 동물 
모델을 사용하여 항암 효능을 평가 하였다. 
이전의 연구에서는 생분해성 폴리머인 폴리에틸렌글리콜과 폴리카프로락톤으로 
구성된 폴리머마이셀에 CFZ 을 loading 하였을 경우 in vitro 실험계에서 대사 안정성이 
향상되었음 이미 보고 한 바가 있다. 이에 본 논문연구에서는 선행 연구되었던 CFZ 을 
포함하는 폴리머마이셀 나노제형(CFZ-PM)의 항암 효능의 향상 여부를 인간 폐암 세포주 
H460 가 이식된 마우스 실험 동물 모델에서 평가하여 보았다. CFZ-PM 를 투약한 마우스에서 
종양 증식 억제효과가 나타나기는 하였지만, 임상적으로 사용되는 사이클로 덱스트린 기반의 
CFZ 제제 (CFZ-CD)보다 우수한 효과를 나타내지는 않았다. 이는 CFZ-PM 의 혈장 
약물동태학 프로파일이 CFZ-CD 과 유사하였고, CFZ-PM 이 이종 이식 마우스에서 자란 
폐암 조직에 대한 CFZ 의 접근성이 증가하지 못하여 폐암 조직에 존재하는 프로테아좀을 
일부만 억제하는 효과를 보였기 때문으로 사료된다. 이러한 결과를 바탕으로, 보다 제제 
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안정성이 높고 효과적으로 CFZ 을 암조직으로 전달 하기 위해 새로운 나노제형의 CFZ 을 
준비하였다.  
친수성이 약한 CFZ 은 쉽게 결정화되는 특징을 갖고 있어 체내 안정성이 높은 
나노크리스탈 제제로 제형화가 가능하리라는 판단 하에  CFZ 을 나노크리스탈 제제로 
개발하였다. 그리고 CFZ 나노크리스탈 제형의 표면은 알부민으로 코팅하여 암세포 및 암세포 
주변에 위치한 알부민 결합 단백질과의 상호 작용을 통해 종양에 대한 약물 전달을 향상시킬 
전략을 세웠다. 알부민이 코팅 된 CFZ 의 나노크리스탈 제제 (CFZ-alb NC)는 280nm 
크기로서 약 80%의 높은 약물 loading content 를 나타내었다. CFZ-alb NC 은 in vitro 와 
in vivo 실험계에서 향상된 대사 안정성을 보였을 뿐만 아니라, CFZ solution 과 비교하였을 
경우 사람의 여러 유방암 세포주에서 향상된 세포 침투 능력 및 세포 독성 효과를 나타냈다. 
또한 CFZ-alb NC 을 마우스의 유방암 세포주인 4T1 가 이식된 BALB/C 마우스 orthotopic 
유방암 실험 동물 모델에 투약 하였을 경우 부작용이 없이 CFZ-CD 보다 더 향상된 항암 
효과를 나타냈다. 이는 CFZ-alb NC 에 코팅된 알부민이 유방암 조직에 과발현 되어있는 
알부민 결합 단백질인 SPARC 가 관여하는 전달 메커니즘에 기반함을 검증하였다. 이 연구를 
통해 유방암 치료에 적용 가능한 CFZ-alb NC 나노입자 제제화의 잠재력을 입증하였다. 
 
주요어: 프로테아좀 저해제, carfilzomib, 나노제형, 폴리머마이셀, 나노크리스탈, 알부민, 
고형암 
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